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Irritable bowel syndrome (IBS) is a functional bowel disorder with 6.5% worldwide
prevalence that causes gas production, abdominal distension, and abdominal pain or discomfort.
This systematic review describes efficacy of the Low-Fermentable Oligosaccharides,
Disaccharides, Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD) to
alleviate IBS symptoms using the PRISMA guidelines. Nine randomized controlled trials (RCT)
and one non-RCT consecutive controlled study published between 2015 to 2019 were identified
using PubMed and CENTRAL. Included studies involved adult IBS participants with symptoms
of abdominal pain, constipation, and/or diarrhea. A total of 530 participants completed the
interventions from the 10 studies included in the final systematic review with participants
ranging from mean ages of 40.31±12.83 years. The LFD can be recommended to patients for its
use with alleviating abdominal pain severity and quality of life; however, more research is
needed to verify the efficacy of the LFD concerning stool frequency and consistency.
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CHAPTER I
INTRODUCTION
Prevalence and diagnostic criteria
Irritable bowel syndrome (IBS) is one of the most common chronic functional
gastrointestinal (GI) disorders that is characterized by altered stool form or frequency in
association with abdominal discomfort or pain without diagnosis of organic disease (Longstreth
et al., 2006, p. 1481; Lacy et al., 2016, pp. 1394, 1396). In the United States, Canada, and the
United Kingdom, more than 1 in every 4 adults has one of the six functional bowel disorders:
unspecified bowel disorder (9.1%), functional constipation (7.8%), functional diarrhea (4.7%),
IBS (4.6%), functional bloating (3.1%), and opioid-induced constipation (1.5%) (Palsson et al.,
2020, p. 1262).
Irritable bowel syndrome has a worldwide prevalence of 3.8% according to the most
recent diagnostic criteria, the Rome IV (Oka et al., 2020, p. 4). Worldwide prevalence according
to previous diagnostic criteria, the Rome III, was higher at 9.2% (Oka et al., 2020, p. 4).
According to the Rome III criteria, 8.8% of Americans are affected by IBS, while 4.8% of
Americans have been diagnosed with IBS under the Rome IV criteria (Palsson et al., 2020, p.
1270). More women have been diagnosed with IBS than men according to the Rome III criteria
(12.0% [95% CI 9.3–15.0] versus 8.6% [6.3–11.2]; odds ratio 1.46 [95% CI 1.33–1.59]), though
there are no studies reporting IBS prevalence according to sex with the Rome IV criteria (Oka et
al., 2020, p. 6). Irritable bowel syndrome is diagnosed 1.46 times more in women than in men.
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Irritable bowel syndrome is commonly diagnosed in women who are younger than 50 years of
age (Mansueto et al., 2015, p. 7090).
According to Rome III and Rome IV criteria, IBS is classified by predominant stool
patterns (see Table 2.1 and Table E.2): IBS with constipation (IBS-C), IBS with diarrhea (IBSD), IBS with mixed bowel habits (IBS-M), and IBS unclassified (IBS-U, where there is
insufficient abnormality of stool consistency). The diagnosis of IBS can be difficult since the
symptoms can vary; for example, one may experience symptoms of constipation or diarrhea but
may not be classified as meeting Rome II criteria for diarrhea or constipation (Thompson et al.,
1999; Drossman et al., 2005, p. 587).
There is no diagnostic gold standard test or biomarker for IBS; instead, symptom-based
diagnostic criteria were developed, starting with the Kruis criteria and Manning criteria
(Manning et al., 1978; Kruis et al., 1984), and the Rome criteria, with the Rome III criteria in use
since 2006 (Longstreth et al., 2006) and the Rome IV criteria updated in 2016 (Lacy et al., 2016)
(see Table C.1). One major difference between the two latest criteria is that Rome IV removed
the term "abdominal discomfort." The Rome III criteria requires that abdominal pain be
experienced at least 3 days per month in the last 3 months, while the Rome IV criteria decreased
the frequency to at least 1 day per month in the last 3 months (see Table C.1). Therefore, the
Rome IV criteria is more limited than its precursor which has caused fewer people to be
diagnosed with IBS when they otherwise have symptoms.
Pathophysiology
Irritable bowel syndrome remains a problem, causing symptoms of gas production,
abdominal distension, and abdominal pain or discomfort (El-Salhy & Gundersen, 2015, p. 1).
Irritable bowel syndrome causes the intestines to react differently and more drastically than
2

normal, causing further irritation more frequently than normal with symptoms such as abdominal
pain, diarrhea, constipation, or a mixture of diarrhea and constipation (Chong et al., 2019, p. 1).
The exact cause of IBS is not known since the GI tract is generally viewed as functioning
normally when an endoscopy is performed. Some believed causes are anxiety and depression
(Holtmann et al., 2016, p. 134). Strangely enough, in one study of IBS patients and psychiatric
disorders, patients experienced mood disorders and anxiety as a result of IBS symptoms
(Holtmann et al., 2016, p. 134). If maintained properly, one can live with this disorder through
proper dietary management.
Due to the symptoms of abdominal discomfort or pain, abnormal bowel habits, bloating,
and abdominal distension, patients experience a reduced quality of life (Mansueto et al., 2015, p.
7090). Irritable bowel syndrome is caused by several factors that result in dysregulation of the
gut-brain axis (Hayes et al., 2014b, p. 165). Dysregulation refers to the "abnormal or imperfect
regulation, esp. [especially] of a metabolic, physiological, or psychological process"
("Dysregulation," 2018). This gut-brain axis refers to the brain signals not appropriately
communicating with the gut. The gut-brain axis can be described by peripheral and central
abnormalities, such as gut dysmotility, visceral hypersensitivity, low-grade mucosal
inflammation, increased intestinal permeability, and altered microbiota (Cozma-Petruţ et al.,
2017, p. 3772; Hayes et al., 2014b, p. 165).
Gut dysmotility
When properly functioning, muscles of the GI tract undergo a complex process that
occurs over several stages, which moves food from the mouth to the esophagus, through the
bowel, and out through the anus (Nowak et al., 2013). The nerves have signals that tell the
muscles to contract and the bowel muscles contract together (Nowak et al., 2013). Intestinal, or
3

gut dysmotility, describes symptoms that occur when there is abnormal gut function and the gut
is not properly moving contents of food, drinks, medications, and other substances along (Nowak
et al., 2013). Dysmotility refers to the process of the intestinal tract losing its ability to
coordinate the bowel muscular contractions (Nowak et al., 2013). There are several causes of
motility changes; for example, an anxious person may have increased gut motility, but this may
not mean dysmotility is occurring.
Visceral hypersensitivity
Gravina et al. (2020, pp. 1-2) notes that visceral hypersensitivity, alterations in GI motor
activity, and psychological stress are precursors to IBS. Visceral hypersensitivity is a condition
describing acute levels of pain in the digestive tract due to oversensitivity to stimuli, alterations
in GI motor activity, and psychosomatic causes; thus, an increase of abdominal pain occurs
(Gravina et al., p. 2). Visceral hypersensitivity is a pathophysiological disturbance in any or all
of immune, neural, endocrine, and metabolic processes and can occur when there is lack of
certain bacteria to support the gut microbiota (Harper et al., 2018, p. 7). In other words,
insufficient bacteria can result in negative outcomes such as abdominal pain, diarrhea, and/or
constipation.
Low-grade mucosal inflammation
A disruption of the microbial balance causes a malfunction of the mucosal immune
system that can result in a number of low-grade inflammation (Akiho et al., 2010, p. 99). Lowgrade inflammation of the GI tract could be caused by infection, diet, and/or antibiotics (Akiho et
al., 2010, p. 99). For example, Malinen et al. (2005) showed that IBS-D patients had decreased
levels of Lactobacillus species, while IBS-C patients had increased Veillonella species.

4

Increased intestinal permeability
Increased intestinal permeability, or leaky gut syndrome, describes the epithelial wall
function and structure weakening, which results in abnormal gut absorption causing material to
seep into the lumen and move into abnormal areas such as the bloodstream, other organs, or
adipose tissue (McLeod et al., 2019). The bowel contains a coating of a single layer of cells
called the mucosal barrier, which separates the gut from the rest of the body ("Leaky Gut
Syndrome," 2018). The mucosal barrier absorbs nutrients and keeps toxic material, such as
germs and large molecules, from entering the bloodstream ("Leaky Gut Syndrome," 2018). This
protects the body from developing illnesses and other complications ("Leaky Gut Syndrome,"
2018). Sometimes, the barrier may become over permeable, or "leaky," which could cause
serious problems ("Leaky Gut Syndrome," 2018).
Altered microbiota
Microbiota are the microorganisms present in the gut (GI tract). An imbalance of the
microbiota may cause low-grade inflammatory responses (Lee & Bak, 2011, p. 254). For
example, IBS patients have been known to have small bowel bacterial overgrowth (Posserud et
al., 2007; Pimentel et al., 2011). Like low-grade mucosal inflammation, the microbiota can also
be altered by GI infections and antibiotics, which has been known to cause IBS symptoms
(Spiller & Campbell, 2006). The level of microbiota that may cause IBS symptoms is not known
or consistent, although it is believed to be caused by increased quantity (Lee et al., 2011, p. 254).
There are no specific bacteria or molecular organic markers to diagnose IBS (Lee et al., 2011, p.
254). Humans have a very diverse microbiota with approximately 3.8·1013 bacteria in the human
body, which vary based on water absorption that surrounds bacteria in the colon, bacterial
growth during transit time, and bacteria shedding from the mucosal surface; so, this can make it
5

difficult to differentiate among them (Sender et al., 2016; Lee et al., 2011, p. 254). Reasons for
microbiota composition differences among individuals include cultural foods in certain regions
and countries, such as yogurts, fermented foods, and medicinal administration (Lee et al., 2011,
p. 254).
Non-diet approaches
Irritable bowel syndrome has been treated with nondietary approaches, such as
hypnotherapy and yoga. Gut-directed hypnotherapy can improve IBS symptoms but has no
major effects when combined with the Low-Fermentable Oligosaccharides, Disaccharides,
Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD) (Peters et al., 2015
& Peters et al., 2016). Gut-directed hypnotherapy has been known to lower fasting distal colonic
motility (Whorwell et al., 1992). In terms of visceral sensitivity, IBS-D patients experienced
improved rectal sensitivity (Prior et al., 1990), while the same result was later improved in the
other subtypes (Lea et al., 2003).
Yoga improved symptoms of quality of life, global improvement, and physical
functioning versus the non-yoga group in a study with 273 patients (Schumann et al., 2016).
When yoga was combined with the LFD, it resulted in reduction of GI symptoms, but there were
no significant differences between groups (Schumann et al., 2018).
The Rome IV criteria (Lacy et al., 2016, p. 1398) lists nondietary approaches for treating
IBS-D: opioid agonists, bile salt sequestrants, probiotics, antibiotics, and 5-HT3 antagonists.
Nondietary approaches for treating IBS-C include mixed opioid agonists/antagonists, psyllium,
polyethylene glycol, chloride channel activators, and Guanylate Cyclase C agonists. Nondietary
approaches for treating IBS with abdominal pain include smooth muscle antispasmodics,
peppermint oil, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), chloride
6

channel activators, Guanylate cyclase C agonists, and 5-HT3 antagonists (Lacy et al., 2016, p.
1398).
Diet management
The GI symptoms of IBS can be managed with dietary changes, such as diets listed in
Table 1.1. The Rome IV criteria discusses alleviating symptoms of IBS-D with low/no gluten or
an LFD (Lacy et al., 2016, p. 1398). The LFD is described in detail in Table B.1. The Rome
Foundation is a non-profit organization that has been providing information for over 20 years
regarding diagnosing and treating Disorders of Gut-Brain Interactions, also called Functional GI
Disorders ("About the Rome Foundation," 2021). This information is made accessible with the
collaboration of scientists and clinicians around the world, which can be used in research and
clinical practice ("About the Rome Foundation," 2021).
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Table 1.1

Common Diets Used to Alleviate Symptoms of IBS

Type of Diet

Diet Description

Supporting Evidence

Lactose-free diet

No lactose-containing products, but can include lactose
products if treated with lactase (lactose-free cow's milk,
lactose-free yogurt, lactose-free ice cream)

Effective for IBS patients with lactose
intolerancea,b

Low fructose/fructans diet

Avoid foods high in fructose and fructans (wheat, rye,
onions, garlic, artichokes)

Backed up by RCTs and observational
studies; IBS patients with breath tests
proving fructose malabsorption
Benefits highly reliant on patient
compliancec,d,e

Paleolithic diet

Only foods available during the Paleolithic era: seafood,
lean meat, fruits, vegetables, nuts, and seeds; no
processed food, dairy, added salt, added sugar, grains,
legumes, or alcohole

No studies available

Specific carbohydrate diet

Reduce consumption of disaccharides and
polysaccharides

Results not significant compared to LFDf

IgG-based avoidance diet

Exclude foods to which patients have increased serum
IgG antibodies

IBS patients compared to placebo seem to
have high levels of IgG antibodies to
common foods (egg, crab, shrimp,
soybean, wheat); symptom severity does
not correlate with antibody tiersg
Small reduction in symptoms; varies with
IBS patient compliance (10-26%) when
compared to a Sham dieth

Very low–carbohydrate diet or
ketogenic diet

Maximum of 20 grams of carbohydrates per day
About 5% of daily calories come from
carbohydrates, compared to the national average of
55%i

Only one study has tested the very low
carbohydrate diet with 13 IBS-D
patients ; 77% of patients (10/13)
reported adequate relief of symptoms:
stool frequency and consistency, quality
of life, and pain scoresj

Fiber supplementation

Psyllium supplement

Several RCTs and a meta-analysisk
Compared to placebo, soluble fiber is
slightly more effective at reducing IBS
symptoms; insoluble fiber is ineffective

Low-fat diet

Less than 27 grams of per day with a daily diet of 2,000
calories l

Several observational studies and
noncontrolled trials to induce or evaluate
symptoms, but no RCTsm
A high-fat diet can provoke symptoms in
IBS patients
Lowering fat in the diet could benefit
patients, especially those with meal-related
abdominal painn-t

Low-fiber diet

Less than 10-15 g of fiber/dayu

No evidence available
Common practice is to advise IBS-D
patients to decrease fiber intake to increase
transit time
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Table 1.1 (continued)
Type of Diet

Diet Description

Supporting Evidence

Low-histamine diet

Decrease the amount of histamine-releasing foods.
Avoid alcoholic beverages, processed or semiprocessed
oily fish, shellfish, cured meat, aged cheeses, fermented
foods, chocolate, eggs, some specific fruits (eg, kiwi,
citrus, pineapple, papaya), and nutsv

No studies for adult IBS patients
Several studies for dermatologic conditions
(chronic spontaneous urticariaw and atopic
dermatitisx ), and one study for pediatric
patients with chronic digestive complaints. v
No
evidence to support this diet for IBS
currently

Sources: Table adapted from Werlang, Palmer, and Lacy (2019). a.Böhmer and Tuynman (2001). b.Vernia, Ricciardi, Frandina, Bilotta, and Frieri
(1995). c.Shepherd, Parker, Muir, and Gibson (2008). d.Skodje, Sarna, Minelle, Rolfsen, Muir, Gibson, Veierød, Henriksen, and Lundin (2018).
e.
Gibson Varney, Malakar, and Muir (2015). f.Vincenzi, Del Ciondolo, Pasquini, Gennai, and Paolini (2017). g.Zuo, Li, Y.Q., Li, W.J., Guo, Lu,
and Desmond (2007). h.Atkinson, Sheldon, Shaath, and Whorwell (2004). i.Lacy (2015). j.Austin, Dalton, Hu, Morris, Hankins, Weinland,
Westman, Yancy Jr, and Drossman (2009). k.Moayyedi, Quigley, Lacy, Lembo, Saito, Schiller, Soffer, Spiegel, and Ford (2014). l. "Dietary
Guidelines for Americans 2015-2020" (2015). m.McKenzie, Thompson, Gulia, and Lomer (2016). n.Böhn, Störsrud, Törnblom, Bengtsson, and
Simrén (2013). o.Faresjö, Johansson, Faresjö, Roos, and Hallert (2010). p.Hayes, Corish, O’Mahony, and Quigley (2014). q.Simrén, Månsson,
Langkilde, Svedlund, Abrahamsson, Bengtsson, and Björnsson (2001). r.Serra, Salvioli, Azpiroz, and Malagelada (2002). s.Simrén, Abrahamsson,
and Björnsson (2007). t.Caldarella, Milano, Laterza, Sacco, Balatsinou, Lapenna, Pierdomenico, Cuccurullo, and Neri (2005). u.Werlang, Palmer,
& Lacy (2019). v.Rosell-Camps, Zibetti, Pérez-Esteban, Vila-Vidal, Ferrés-Ramis, and García-Teresa-García (2013). w.Son, Chung, Kim, & Park
(2018). x.Chung, Cho, Ahn, Lee, H. B., Kim, Park, & Lee, C. H. (2011).

Diagnosis
Between 1978 and 2016, the criteria for diagnosing IBS were updated five times before
the current guidelines—the Rome IV criteria—were published (see Appendix D and Appendix
E). It has been difficult to diagnose IBS since symptoms can change over time, symptoms could
be similar to organic diseases, providers may not always be up to date on the diagnosis of IBS
and its guidelines and definitions, lack of single biomarker to diagnose, and routine tests usually
yield normal results (Lacy et al., 2017, p. 2).
Manning criteria
Manning et al. (1978) first published the IBS diagnostic criteria that continue to be
studied today (see Table C.1 and Figure D.1). Irritable bowel syndrome related symptoms were
compared to those in organic diseases, which are those that can be diagnosed with routine tests
such as X-Rays, Computed Tomography (CT) Scans, Magnetic Resonance Imaging (MRI),
colonoscopy, and endoscopy. A major limitation of the seminal study done in Manning et al.
9

(1978) is that it compared patient records for only 65 patients total, 32 with IBS, and 33 with
organic disease. Patients with pain-related IBS (most common) differentiated from organic
disease by having symptoms of abdominal distension, pain relief with a bowel movement, more
frequent stools with onset of pain, and looser stools with the onset of pain (Manning et al., 1978).
The presence of mucus and feelings of incomplete evacuation area were also identifiable
symptoms of IBS (Manning et al., 1978). Manning et al. (1978) described 15 common symptoms
in which at least three of these symptoms resulted in a positive IBS diagnosis: 1) looser stools at
onset of pain, 2) more frequent bowel movements at onset of pain, 3) pain eased after bowel
movement (often), 4) visible distension, 5) feeling of distension, 6) mucus per rectum, 7) feeling
of incomplete emptying (often), 8) bowel movement before breakfast, 9) nocturnal bowel
movement, 10) urgency of defecation, 11) pain worse after bowel movement, 12) pain eased
with flatus, 13) >2 bowel movements between meals, 14) harder stools at onset of pain (least
common, and/or 15) less frequent bowel movements at onset of pain (least common) (see Table
C.1). The Manning et al. (1978) criteria failed to address duration of symptoms and subtype
identification; the researchers also did not distinguish IBS-C from IBS-D which should be
differentiated due to them involving different stool consistencies (see Table E.1) (Manning et al.,
1978).
Kruis criteria
Kruis et al. (1984) utilized a logistic regression analysis and scoring system for diagnosis
and emphasized the importance of properly ruling out organic disease prior to diagnosing IBS
(see Table C.1 and Figure D.1). Irritable bowel syndrome and organic disease were difficult to
differentiate since they can have some of the same signs and symptoms, however, Kruis et al.
(1984) found certain symptoms more common in IBS than in organic disease. The most common
10

IBS symptoms were bowel movement irregularities; mixture of abdominal pain, flatulence, and
bowel movement irregularities; and alternating bowel habits (constipation/diarrhea) with
symptoms lasting more than 2 years, while organic disease symptoms were abdominal pain and
flatulence with symptoms lasting more than 2 years (Kruis et al., 1984). The Kruis et al. (1984)
criteria emphasized a patient questionnaire, physical examinations, and laboratory tests, which
were too extensive for clinical practice use; a simpler way to diagnose IBS was needed.
Rome I criteria
The Rome I criteria were published in 1990 (see Table C.1 and Figure D.2) and described
functional GI disorders as "a variable combination of chronic or recurrent GI symptoms not
explained by structural or biochemical abnormalities" (Drossman et al., 1990, p. 159). Functional
GI disorders were classified into symptom-based criteria subgroups according to clinical
experience, epidemiological data, and assessment of treatment trial (Drossman et al., 1990).
Diagnostic criteria for functional GI disorders were classified if symptoms were chronic or
recurrent for at least three months and the symptoms were not attributed to other GI disease
based on adequate medical evaluation (Drossman et al., 1990). Irritable bowel syndrome was
defined as "a functional gastrointestinal disorder attributed to the intestines and associated with
symptoms of: (a) abdominal pain, and/or (b) disturbed defaecation, and/or (c) bloatedness or
distension" (Thompson et al., 1989; Drossman et al., 1990, p. 164). Patients reported symptoms
regardless of having chemical, radiological, or physiological abnormalities. The Rome I criteria
failed to distinguish abdominal bloating from abdominal pain. This was significant since patients
can experience bloating without pain and/or pain without bloating.

11

Rome II criteria
The Rome II criteria (Thompson et al., 1999) were established in 1999 and required that
patients have symptoms for at least 12 nonconsecutive weeks (see Table C.1 and Figure D.2). It
added "abdominal discomfort" to "pain" in the definition and "onset" was added to the relevant
symptoms (Thompson et al., 1999). Rome II required that IBS patients experienced two out of
the three abdominal pain-related criteria to confirm that altered bowel habits were present: (1)
Relieved with defecation; and/or (2) Onset associated with a change in frequency of stool; and/or
(3) Onset associated with a change in form (appearance) of stool (Thompson et al., 1999). Bowel
habits were not classified into specific subtypes (Thompson et al., 1999). This was significant
since patients were diagnosed with IBS, but they did not know which type they were according
to stool consistencies.
Rome III criteria
The Rome III criteria (Longstreth et al., 2006) were published in 2006 and were the first
to classify IBS by subtypes (see Table C.1 and Figure D.3). Irritable bowel syndrome was
defined as "a functional bowel disorder in which abdominal pain or discomfort is associated with
defecation or a change in bowel habit, and with features of disordered defecation" (Longstreth et
al., 2006, p. 1480). The Rome III subtypes were based on predominant stool pattern/consistency
rather than stool frequency (see Table E.2) (Longstreth et al., 2006, p. 1481). Symptoms that
were not in the diagnostic criteria included the following: abnormal stool frequency ([a] ≤3
bowel movements per week or [b] >3 bowel movements per day), abnormal stool form ([c]
lumpy/hard stool or [d] loose/watery stool), [e] defecation straining, [f] urgency, or also a feeling
of incomplete bowel movement, passing mucus, and bloating (Longstreth et al., 2006, p. 1481).
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Bloating was no longer listed as a primary symptom since it was not specific enough for IBS.
This was significant since it described stool consistencies (constipation/diarrhea) and more
specific symptoms, whereas other criteria did not describe these symptoms.
Rome IV criteria
The Rome IV criteria define the most recent and currently used criteria (see Table C.1
and Figure D.3). Irritable bowel syndrome is "[a functional bowel disorder] in which recurrent
abdominal pain is associated with defecation or a change in bowel habits" (Lacy et al., 2016, p.
1393). Criteria for diagnosing IBS occur at least 6 months before diagnosis with symptoms
present in the last 3 months: "Recurrent abdominal pain, on average, at least 1 day per
week in the last 3 months, associated with 2 or more of the following criteria: (1) Related to
defecation, (2) Associated with a change in frequency of stool, and (3) Associated with a change
in form (appearance) of stool" (Lacy et al., 2016, p. 1394).
The word "discomfort" is no longer used since it has multiple meanings in different
languages and there are issues with distinguishing pain and discomfort as qualitative or
quantitative (Lacy et al., 2016). Depending on the context, "discomfort" could refer to painful,
general uncomfortable feeling, embarrassment, and therefore, more precise wording was needed
to establish a more specific and universal definition.
Bloating and distension are two common symptoms, and this is similar to the symptoms
described by Manning et al. (1978) and the Rome I criteria (Drossman et al., 1990). The
frequency of abdominal pain increased from three days per month to one day per week on
average due to data retrieved from the Rome Normative GI symptom survey, which showed
increased sensitivity and specificity in a large population (Whitehead & Palsson, 2014).
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The Rome IV criteria identifies disordered bowel habits as constipation, diarrhea, or a
mix of constipation and diarrhea with symptoms of bloating/distention (Lacy et al., 2016).
Finally, the Rome IV criteria bases predominant bowel habits for subtyping and does not relate
this to the number of days without a bowel movement (Lacy et al., 2016). A patient's specific
bowel movements increase the specificity of bowel subtyping only on days the patient is having
abnormal bowel movements (Lacy et al., 2016). Irritable bowel syndrome can have symptoms
that are manageable to acute in which treatment type depends on severity, lifestyle, and
medications.
Carbohydrates
Many people with IBS are intolerant to certain fermentable oligosaccharides,
disaccharides, and monosaccharides since they are difficult to digest. Carbohydrates are the most
prevalent organic compounds which are the principal source of nutrients used by living
organisms for energy (“Carbohydrates,” 2021). There are simple carbohydrates and complex
carbohydrates. Simple carbohydrates (simple sugars) include monosaccharides and disaccharides
(“Carbohydrates,” 2021). Complex carbohydrates include oligosaccharides and polysaccharides
(“Carbohydrates,” 2021).
Monosaccharides
Monosaccharides (mono– = “one”; sacchar– = “sweet”) the simplest sugars, (fructose and
glucose) are the building blocks of carbohydrates that provide energy to cells and cannot be
broken down by hydrolysis (“Carbohydrates,” 2021; “Carbohydrates,” n.d.). Hydrolysis is a
chemical process in which a bond is split by adding water; hydrolysis reactions break bonds and
release energy ("Hydrolysis," 2021). The most nutritionally important and plentiful
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monosaccharide is glucose. Glucose is involved in the digestion of other carbohydrates, while
fructose is present in fruits (“Carbohydrates,” 2021).
Disaccharides
Disaccharides (di– = “two”) (most common are maltose, lactose, and sucrose) have two
monosaccharide units joined by covalent bonds (“Carbohydrates,” n.d.; Gropper et al., 2012, p.
65). Similar to monosaccharides, disaccharides also provide nutrients in the diet (Gropper et al.,
2012, p. 65). Maltose contains two glucose units and is in malt beverages such as beer and malt
liquors (Gropper et al., 2012, p. 65). Lactose is naturally found in milk and milk products.
Sucrose (table sugar, cane sugar, beet sugar) is the most vital disaccharide since it is widely used
as a natural sweetener (“Carbohydrates,” 2021; Gropper et al., 2012, p. 65). Sucrose is composed
of the monosaccharides glucose and fructose (“Carbohydrates,” 2021).
Oligosaccharides
Complex carbohydrates (oligosaccharides and polysaccharides) store energy and form
structures of living organisms (“Carbohydrates,” 2021). Oligosaccharides are monosaccharide
short chain units joined by covalent bonds and have 3-10 saccharide units, which are flatulent
sugars present in legumes and grains (Gropper et al., 2012, p. 61). Oligosaccharides include
raffinose (a trisaccharide), stachyose (a tetrasaccharide), and verbascose (a pentasaccharide)
which are composed of glucose, galactose, and fructose and found in beans, peas, bran, and
whole grains (Gropper et al., 2012, p. 66). These oligosaccharides are not broken done with
water (hydrolyzed), but the intestines have bacteria that digests them, and this can produce gases
and cause flatulence (Gropper et al., 2012, p. 66). Another type of oligosaccharide are dextrins
(made from starch) which are hydrolyzed under controlled conditions to make glucose chains of
desired lengths (Gropper et al., 2012, p. 66). Shorter chain dextrins (3-20 units) are commonly
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used in food and drug applications, and listed on food labels as maltodextrin, corn syrup solids,
or hydrolyzed corn starch. Dextrin classification is based on specific chain length, which would
classify them as oligosaccharides or polysaccharides (Gropper et al., 2012, p. 66).
Polysaccharides
Polysaccharides are monosaccharide long chain units that number from hundreds to
thousands of glucose units and have more than 10 saccharide units (Gropper et al., 2012, p. 62).
The main polysaccharides are starch, glycogen, and cellulose. Plants use starch to store energy
and an example is potato storing starch in underground tubers (stems that grow underground)
(“Carbohydrates,” 2021). Animals use glycogen to store energy and an example is human storing
glycogen in liver cells (“Carbohydrates,” 2021). Plants use cellulose to create rigid walls around
cells (“Carbohydrates,” 2021). Polysaccharides, or starch, are the form of carbohydrates that
need to be broken into smaller units (monosaccharides) so that the body can use them.
FODMAPs
FODMAPs are short-chain carbohydrates that are poorly absorbed by the intestine,
extract excess water into the intestine, and are quickly fermented by bacteria in the gut (King,
2020). A patient’s tolerance to FODMAP foods varies, but if he or she consumes a certain
amount, there could be adverse reactions: increased gassiness, bloating, abdominal pain, and
diarrhea (King, 2020). Table C.1 lists high and low FODMAP foods. FODMAPs are named
based on their carbohydrate chain length and each person's response to each variation depends on
symptom type and severity (Barrett, 2017 p. 8).
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Oligosaccharides
Oligosaccharides contain the longest chain length compared to the other FODMAP
carbohydrates and are classified into two groups: fructo-oligosaccharides (fructans) or FOS and
galacto-oligosaccharides (galactans) or GOS (Barrett, 2017; King, 2020). Fructans are in wheat
products, onions, garlic, artichokes, and inulin (King, 2020). Galactans are in lentils, chickpeas,
broccoli, beans, Brussels sprouts, and soy-based products (King, 2020). Humans do not have
enzymes that can breakdown fructans and galactans, therefore they are malabsorbed in everyone
(Rumessen & Gudmand-Hoyer, 1998; Macfarlane et al., 2008). When fructans and galactans
travel to the colon, they become fermented to form gases and short-chain fatty acids; thus, they
result in gas production when they interact with colonic bacteria; and this is believed to be a
major contributor to bloating, abdominal pain, and excessive flatulence seen in IBS patients
(Murray et al., 2014, p. 116).
Disaccharides
Disaccharides include mainly lactose, which is a sugar that needs lactase for absorption
(Barrett, 2017; King, 2020). Disaccharide examples are milk, yogurt, soft cheeses, ice cream, and
puddings (King, 2020). When individuals are unable to digest lactose in the small intestine, it is
called lactose malabsorption, while those with lactose intolerance experience symptoms of
bloating, gas, and diarrhea upon ingestion of foods or drinks containing lactose (Storhaug et al.,
2017; Law et al., 2010). Lactose malabsorption is prevalent in 68% of the global population
standardizing for country size; with 28% in western, southern, and northern Europe to 70% in the
Middle East (Storhaug et al., 2017). Asian and Mediterranean ethnic backgrounds seem to be
more common with lactose malabsorption with 58% in Pakistan to 100% in South Korea; and
16% in Cyprus and 28% in Saudi Arabia (Storhaug et al., 2017, p. 741). Less lactose activity is
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present in these ethnic backgrounds due to lower consumption of lactose in their diets, increasing
age, and during periods of intestinal inflammation (like active Crohn's Disease) (Barrett, 2017;
Storhaug et al., 2017). Lactose malabsorption can be diagnosed using breath hydrogen and
methane testing (Rosado, & Solomons, 1983); and if diagnosed, lactose-free products can be
consumed such as lactose-free milk, low-lactose cheese, and lactose-free ice cream.
Monosaccharides
Monosaccharides (fructose) are the smallest FODMAP carbohydrate, which contribute to
a high osmotic effect and bring water into the bowel lumen, causing the small intestine to
become distended (since the small intestine poorly absorbs fructose), which can cause a person
to feel abdominal pain and bloating (Barrett, 2017, p. 9; Murray et al., 2014, p. 116). Fructose is
a single sugar found in fruits such as apples, pears, watermelon, and mangoes (King, 2020;
Barrett, 2017, p. 9). Fructose also includes sugar snap peas, agave, honey, and high fructose corn
syrup (King, 2020; Barrett, 2017, p. 9). A large fructose consumption, for example with a
hydrogen breath test, can cause diarrhea or altered motility (Barrett, 2017, p. 9). If a person does
not have a fructose malabsorption, it is possible for he or she to still have IBS symptoms due to
fructose.
Polyols
Polyols (sugar alcohols ending in -ol), are common in sorbitol and mannitol (Barrett,
2017, p. 9). Sorbitol is present in certain fruits (stone fruits: cherries and nectarines), apples, and
pears, while mannitol are higher in certain vegetables (mushrooms, cauliflower, snow peas)
(King, 2020; Barrett, 2017, p. 9). Additional sugar alcohols/substitutes include xylitol, erythritol,
isomalt (made from sucrose), maltitol, sugar-free chewing gums, and mints (King, 2020; Barrett,
18

2017, p. 9). Similar to fructose, the small intestine also poorly absorbs sorbitol and mannitol,
then bacteria ferment them, and this causes GI symptoms to occur (Yao et al., 2014, p. 2; Barrett,
2017, p. 9). A person can lack a polyol malabsorption and can still have IBS symptoms due to
polyols (Barrett, 2017, p. 9). It is inconclusive whether sorbitol malabsorption with or without
fructose causes more issues in IBS patients since one study showed a difference (FernandezBanares et al., 1993), while another study showed there to be no difference (Nelis et al., 1990).
Nevertheless, of these contradictory findings, sorbitol and mannitol-rich foods can appropriately
be restricted in individuals having GI symptoms (Yao et al., 2014, p. 2).
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CHAPTER II
LITERATURE REVIEW
The low-FODMAP diet
The Department of Gastroenterology at Monash University in Melbourne, Australia
discovered FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and
Polyols) foods in 2005, which are short-chain carbohydrates that are poorly absorbed or
impossible to digest by the small intestine ("First in FODMAP Research," 2019). There are highFODMAP and low-FODMAP foods that have been classified into groups, which include specific
fruit, vegetables, breads, cereals, nuts, legumes, dairy products, and processed foods (Table C.1).
The LFD has been used in clinical practice to decrease GI symptoms. Foods high in FODMAPs
can be IBS triggers since their small size brings in water into the small intestine and travel to the
large intestine, where they are fermented by resident gut bacteria and make gas ("First in
FODMAP Research," 2019). These excess gases in the gut stretch the bowel wall and trigger IBS
symptoms of abdominal pain, gas and bloating, distension, constipation, and diarrhea ("First in
FODMAP Research," 2019).
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Prior systematic reviews
The LFD is the most frequently recommended diet to treat IBS (Dimidi, 2020, p. 4) and
should be implemented by a registered dietitian nutritionist (RDN) (Barrett, 2017).
Three previous meta-analyses on the LFD efficacy to alleviate symptoms of IBS were
published in 2018 and 2021 (Dionne et al., 2018; Lanen et al., 2021; and Hahn et al., 2021).
Dionne et al. (2018) conducted a meta-analysis of RCTs to study the efficacy of the LFD
and gluten-free diets to improve global IBS symptoms and abdominal pain in IBS patients.
Dionne et al. (2018) evaluated 9 studies published between 2011-2017 (Biesiekierski et al., 2011;
Shahbazkhani et al., 2015; Staudacher et al., 2012; Eswaran et al., 2016; McIntosh et al. 2017;
Böhn et al., 2015; Halmos et al., 2014; Hustoft et al., 2017; Staudacher et al., 2017).
Lanen et al. (2021) performed a meta-analysis of observational and intervention studies
to explore the LFD efficacy on GI symptoms and quality of life in IBS patients. Lanen et al.
(2021) performed the search until October 2020. Lanen et al. (2021) analyzed 9 parallel trials
and 3 crossover studies that published between 2010-2019 (Böhn et al., 2015; Eswaran et al.,
2016; Halmos et al., 2014; Harvie et al., 2017; McIntosh et al., 2017; Ong et al., 2010; Paduano
et al., 2019; Patcharatrakul et al., 2019; Pedersen et al., 2014; Staudacher et al., 2012; Staudacher
et al., 2017; Zahedi et al., 2018).
Hahn et al. (2021) performed the most recent meta-analysis to date of intervention and
observational studies including RCTs (parallel, cross-over, or factorial design) to compare LFD
to a control group in IBS patients to alleviate symptoms and improve quality of life. Control
groups included those following traditional IBS, habitual, Unrestricted diet, structured dietary
interventions (low-lactose diet, gluten-free diet), supplementation (prebiotics, probiotics), and
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lifestyle changes (yoga, hypnotherapy). Hahn et al. (2021) completed the search up to February
2021. The included studies were published between 2010-2021.
This systematic review is different from the previous three studies (Dionne et al., 2018;
Lanen et al., 2021; and Hahn et al., 2021) since it explored within group efficacy of LFD to
alleviate the following symptoms in IBS patients: abdominal pain/distension/bloating, stool
frequency/stool consistency/dissatisfaction with bowel habits, and quality of life symptoms. This
thesis search was performed January 2021 to July 2021; it included 9 RCTs and one non-RCT
consecutive controlled study conducted 2015-2019.
How to follow the low-FODMAP diet
There are 3 phases of the LFD: 1) LFD for 2-6 weeks; 2) FODMAP reintroduction for 812 weeks; and 3) FODMAP personalization for the long-term ("Treating IBS with a 3-step
FODMAP Diet," 2019). First during the LFD phase, low or moderate FODMAP foods should
replace high-FODMAP foods, with most foods being low in FODMAPs (see Table B.1); if the
IBS symptoms are improved with the LFD, the patient moves onto the next phase ("Treating IBS
with a 3-step FODMAP diet," 2019). Second, the FODMAP reintroduction phase involves
continuing the LFD, but slowly reintroducing FODMAPs ("Treating IBS with a 3-step
FODMAP Diet," 2019). Each FODMAP group should be challenged individually (fructans,
GOS, lactose, fructose, sorbitol, mannitol) ("Treating IBS with a 3-step FODMAP Diet," 2019).
One FODMAP food should be reintroduced each day for 3 days to identify which FODMAPs are
tolerable, and which cause trigger symptoms ("Treating IBS with a 3-step FODMAP Diet,"
2019). Third, FODMAP personalization involves the patient knowing which FODMAP foods are
tolerable and which foods are triggers; the foods that are tolerable can now be included in the
patient's diet ("Treating IBS with a 3-step FODMAP Diet," 2019).
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Even though an LFD has been shown to reduce IBS symptoms if followed for at least six
weeks, the safety of this diet for the long-term is unclear (Gravina et al., 2020, p. 8). A highFODMAP diet (or an Unrestricted diet from here on out) can cause there to be more colonic gas,
mucosal inflammation, and permeability, so visceral hypersensitivity results (Harper et al., 2018,
p. 9). The LFD decreases the amount of bowel gas (Patcharatrakul et al., 2019, p. 2). The poor
absorption of FODMAPs by the small intestine causes symptoms of abdominal pain, discomfort,
and bloating since these carbohydrates increase luminal fluid through osmotic activity
(Patcharatrakul et al., 2019). The unabsorbed carbohydrates travel to the colon and cause
hydrogen and methane to be made by colonic bacterial fermentation; this causes gas production
and luminal distension (Patcharatrakul et al., 2019). Once a person learns “trigger” foods to
avoid, adequate nutrients can be consumed from other foods ("Treating IBS with a 3-step
FODMAP Diet," 2019).
Monitoring IBS symptoms for research purposes
Bristol stool form scale
The Bristol Stool Form Scale (BSFS) was developed in the 1990s in the Bristol Royal
Infirmary in Bristol U.K, England (Lewis & Heaton, 1997). The BSFS is a reliable and valid
stool consistency and stool frequency scale that has been in use since 1997 (Lewis & Heaton,
1997). Its purpose is to describe stool consistency, bowel habits, and stool abnormalities (Lewis
& Heaton, 1997).
The BSFS describes stool frequency (number of stools per day) and mean stool
consistency on a 7-point scale (see Table E.1).Using the BSFS, the Rome IV criteria define the
four IBS subtypes: IBS with predominant constipation (IBS-C), IBS with predominant diarrhea
(IBS-D), IBS with mixed bowel habits (IBS-M), and IBS unclassified (IBS-U) (Lacy et al., 2016,
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p. 1395) (see Table 2.1). There are seven types of stool that describe bowel habits and stool
consistency (see Table E.1) used to define each IBS subtype. The Rome III criteria (Longstreth
et al., 2006) was the first to have subtyping by predominant stool pattern which is described in
Table E.2 and was updated in the Rome IV criteria (Lacy at al., 2016) described in Table 2.1.
The Rome III criteria describes ≤25 or ≥25% of bowel movement as the threshold for
classification (see Table E.2), while the Rome IV criteria updated the criteria to describe <25%
or >25% of bowel movement as the threshold for classification (see Table 2.1) (Longstreth et al.,
2006; Lacy et al., 2016). Both Rome III and Rome IV criteria describe habits occurring without
the use of medications to treat bowel abnormalities.

Table 2.1

Rome IV Subtyping IBS by Predominant Stool Pattern

IBS Subtype
IBS-C (IBS with predominant
constipation)

Bristol Stool Form Scale Bowel Habit
>25% hard/lumpy stools (types 1-2)
<25% loose/watery stools (types 6-7)

IBS-D (IBS with predominant
diarrhea)

>25% loose/watery (types 6-7)
<25% hard/lumpy (types 1-2)

IBS-M (IBS with mixed bowel
habits)

>25% loose/watery (types 1-2)
>25% hard/lumpy (types 6-7)

IBS-U (IBS Unclassified)

<25% loose/watery
<25% hard/lumpy
Bowel habits cannot be accurately categorized into 1 of
the 3 groups above.
Source: Lacy, Mearin, Chang, Chey, Lembo, Simren, & Spiller, (2016, pp. 1395-1396)
* IBS subtypes related to bowel habit abnormalities (IBSC, IBS-D, and IBS-M) can only be
confidently established when the patient is evaluated off medications used to treat bowel habit
abnormalities.
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IBS-SSS
The Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) is a four-page valid
and reliable questionnaire that has been used in IBS research since 1997 (Francis et al., 1997).
The IBS-SSS uses a Visual Analog Scale (VAS) to measure five items: 1) Severity of abdominal
pain, 2) Frequency of abdominal pain, 3) Severity of abdominal distension, 4) Dissatisfaction
with bowel habits, and 5) Interference with life in general (Francis et al., 1997, pp. 401-402).
This survey is used by several researchers to assess IBS symptoms (see Table F.1 and Table 4.1)
(Böhn et al., 2015; Harvie et al., 2017; Hustoft et al., 2016; McIntosh et al., 2017; Paduano et
al., 2019; Peters et al., 2016; Staudacher et al., 2017; Zahedi et al., 2018). Each question in the
IBS-SSS questionnaire can yield a maximum score of 100, with a total possible score of 0-500; a
higher VAS score indicates more severe symptoms (Francis et al., 1997). The overall IBS-SSS
score classifies the severity of a person's IBS and assesses response to treatment (Francis et al.,
1997). There are 3 groups that define severity: <175, mild IBS; 175-300, moderate IBS; and
>300, severe IBS (Francis et al., 1997). A reduction of ≤50 points is considered a significant
treatment response (Francis et al., 1997).
Purpose
The purpose of this systematic review was to analyze 9 RCTs and one non-RCT
consecutive controlled study that compared the efficacy of the LFD in alleviating symptoms of
IBS. The research findings will add to the knowledge of optimal dietary management for IBS
sufferers.
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CHAPTER III
METHODS
Aim and objectives
The aim of this project was to determine if the LFD is effective to alleviate symptoms of
IBS. The following three objectives were made according to the IBS-SSS questionnaire (Francis
et al., 1997) (see Table F.1):
1. Is the low-FODMAP diet effective in improving abdominal pain, distension, and

bloating in adults with irritable bowel syndrome?
2. Is the low-FODMAP diet effective in improving stool frequency, stool consistency,

and dissatisfaction with bowel habits in adults with irritable bowel syndrome?
3. Is the low-FODMAP diet effective in improving quality of life in adults with

irritable bowel syndrome?
Inclusion criteria
Full text nine RCTs and one non-RCT consecutive controlled study published between
2015 to 2019 were identified using PubMed and CENTRAL and included since they met the
following criteria: 1) published in the English language between 2015-2020; 2) diagnosis of IBS
based on Rome III or IV criteria with any subtype; 3) adults aged 18 and older; 4) no use of
medications for the treatment of bowel habit abnormalities; 5) reported on at least one of the
following: abdominal pain, constipation, and diarrhea symptoms; and 6) compared an Unrestricted
diet to an LFD. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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(PRISMA) guidelines flowchart and criteria were followed in accordance with Moher, et al. (2009)
and elaborated more in Liberati et al. (2009) (see Figure G.1)
Exclusion criteria
Studies were excluded if they met the following criteria (n =185):
1. Incomplete study (9)
2. Could not find full text article (17)
3. Over the counter/prescription medications (24)
4. LFD versus regular and low-FODMAP rye bread (2)
5. Microbiota/metabolome (7)
6. Mindfulness-based eating and mind-body skills (2)
7. Low-FODMAP wheat/rye bread versus regular wheat/rye bread (2)
8. Not diagnosed with IBS (46)
9. Effect of gluten on clinical outcomes (1)
10. Under the age of 18 years old (12)
11. FODMAP impacts on blood glucose (1)
12. LFD versus gluten-free diet (4)
13. Not a clinical study (8)
14. No mention of abdominal pain, constipation, and/or diarrhea
15. Micronutrient intake in LFD (3)
16. Not Unrestricted diet versus LFD (30)
17. Intragastric administration of FODMAPs (4)
18. Artisan wheat bread versus industrial wheat bread (1)
19. Fecal bacterial profiles (1)
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(8)

20. Malabsorptive bariatric surgery and IBS; LFD versus symbiotics (1)
21. Fructose or inulin ingestion (1)
22. Cytokine profiles (1)
Search strategy
The search began in January 2021 and finished in July 2021. The two databases used were
PubMed and CENTRAL (Cochrane Central Register of Controlled Trials). Studies that discussed
participants using the LFD or any elimination diets were reviewed. The studies were selected based
on the following guidelines: 1) Contained the words (irritable bowel syndrome) AND (low
fodmap) AND (diet) AND (food), 2) Discussion of the LFD, and 3) A full bibliography was made
with articles being saved as Portable Document Formats (PDFs).
The search terms used in each database search were “(irritable bowel syndrome) AND
(fodmap)” and “(functional bowel syndrome) AND (fodmap)." Articles chosen were published
between 2015 and 2020 in the English language included irritable bowel syndrome in their title,
and mentioned either diet or nutrition in it, or both.
Screening
A total of 383 articles were screened via manual search and the flow diagram is illustrated
in Figure 4.1. The articles from each search were exported by Excel and highlighted in red if they
did not meet the criteria, highlighted in purple if they were a duplicate, and highlighted in green if
they met the criteria.
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Irritable bowel syndrome and FODMAP in PubMed
The initial search was on “(irritable bowel syndrome) AND (fodmap)” in PubMed and had a total
of 47 results. Of these 47 articles, 32 articles were excluded and 15 were included. Thirty-two
articles were excluded for the following reasons:
•

Not diagnosed with IBS (N= 15)

•

Supplementation with any over the counter/prescription medications (N= 4)

•

Intervention other than Unrestricted diet versus LFD (N= 8)

•

Nutrient intake in LFD (N= 1)

•

Intragastric Administration of FODMAPs (N= 1)

•

Microbiota (N= 1)

•

Low-FODMAP rye bread versus regular rye bread (N= 1)

•

Fecal bacterial profiles (N= 1)

Functional bowel syndrome and FODMAP in PubMed
The second search was on “(functional bowel syndrome) AND (fodmap)” in PubMed and also had
47 results, all of which were duplicates of the first search.
Irritable bowel syndrome and FODMAP in CENTRAL
The third search was on “(irritable bowel syndrome) AND (fodmap)” in CENTRAL and had a
total of 223 results. Seventy-two articles were excluded for being duplicates, and 1 article was
included. Of these 151 articles, 150 articles were excluded.
One-hundred fifty articles were excluded for the following reasons:
•

Incomplete studies (N= 9)

•

Could not find/access full text article (N= 17)
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•

Supplementation with any over the counter/prescription medications (N= 20)

•

LFD vs regular and low-FODMAP rye bread (N= 2)

•

Microbiota/metabolome (N= 6)

•

Mindfulness-based eating (N= 1)

•

Low-FODMAP wheat bread versus regular wheat bread (N= 1)

•

Mind-body skills (N= 1)

•

Not diagnosed with IBS (N= 31)

•

Effect of gluten on clinical outcomes (N= 1)

•

Under the age of 18 years old (N= 12)

•

FODMAP intake impacts on blood glucose and breath hydrogen (N= 1)

•

LFD versus gluten-free diet (N= 4)

•

Not an article (N= 8)

•

No mention of abdominal pain, constipation, and/or diarrhea (N= 8)

•

Micronutrient intake changes in LFD (N= 2)

•

Not LFD versus Unrestricted diet (N= 22)

•

Intragastric administration of FODMAPs (N= 3)

•

Artisan wheat bread versus industrial wheat bread (N= 1)

Functional bowel syndrome and FODMAP in CENTRAL
The final search was on “(functional bowel syndrome) AND (fodmap)” in CENTRAL and had 66
results. Of these 66 articles, 63 studies were excluded for being duplicates and 3 articles were
excluded. Three articles were excluded were excluded for the following reasons:
•

Malabsorptive bariatric surgery and IBS; LFD versus symbiotics (N= 1)
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•

Fructose or inulin ingestion cause more symptoms in IBS patients (N= 1)

•

Cytokine profiles in IBS patients (N= 1)

Final exclusion process
At the end of the initial search and screening, the articles were broken down into their final
numbers: 185 excluded, 182 duplicates, and 16 included for further review. After printing out all
of the articles for a more thorough review, an additional 6 studies were excluded due to
interventions being other than an Unrestricted diet versus LFD and participants not being
diagnosed with IBS. A total of 10 studies were included in the final qualitative synthesis and
described in more detail in Figure 4.1.
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CHAPTER IV
RESULTS
Study selection and description of studies
This systematic review was conducted according to the PRISMA statement and PRISMA
guidelines shown in Figure G.1 (Liberati et al., 2009). Each article included in this systematic
review was checked based on the criteria, with the intervention being LFD versus unrestricted
diet.
Table 4.1 lists the intervention measures done for each study. Information from each
study is listed in Table 4.2, which includes relevant citation information, the country the study
took place, design/methodology, participants' IBS definition and age range, sample size, length
of intervention, predominant stool type, intervention, and main outcome. The publication years
ranged from 2015- 2019. A total of 16 studies met all the inclusion criteria, but 6 studies were
later excluded due to interventions being other than LFD versus Unrestricted diet and
participants not being diagnosed with IBS, so a total of 10 articles were included in the final
systematic review (Figure 4.1). Table 4.3 summarizes the comparison of the results of the 10

included studies to the systematic review objectives of the within LFD group, while Table 4.4
shows between diet group significances.
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Country of origin
The final systematic review contained 10 studies which represented five geographical
regions: North America (United States, Canada), Europe (Sweden, Norway, Italy, United Kingdom),
South Pacific Ocean (New Zealand), Asia (Thailand, Iran), and Australia. Each study represented a
different country.

Duration of study
Studies were conducted for 3 weeks (McIntosh et al., 2017), 4 weeks (Böhn et al., 2015;
Eswaran et al., 2016; Paduano et al., 2019; Patcharatrakul et al., 2019; Staudacher et al., 2017), 6
weeks (Peters et al., 2016; Zahedi et al., 2018), 9 weeks (Hustoft et al., 2017), and 3 months
(Harvie et al., 2017).
Study participants
A total of 962 participants were recruited and 530 completed the interventions from the
10 studies included in the final systematic review. The sample sizes ranged from 20-101
participants, with a mean of 53 participants. A total of 398 females out of 530 participants
completed the intervention, with an average number of 40 females per study, or 75.92% were
female. The average age of participants was 40.31±12.83 years. Table H.1 describes the different
diets in the included studies.
•

Three out of ten studies included participants of all four IBS subtypes (Böhn et
al., 2015; McIntosh et al., 2017; Paduano et al., 2019).

•

Six out of ten studies compared participants with IBS-C (Böhn et al., 2015;
Harvie et al., 2017; McIntosh et al., 2017; Paduano et al., 2019; Patcharatrakul et
al., 2019; Peters et al., 2016).
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•

Nine out of ten studies compared participants with IBS-D.

•

Seven out of ten studies involved participants with IBS-M (Böhn et al., 2015;
Harvie et al., 2017; Hustoft et al., 2017; McIntosh et al., 2017; Paduano et al.,
2019; Peters et al., 2016; Staudacher et al., 2017).

•

Four out of ten studies included participants with IBS-U (Böhn et al., 2015;
McIntosh et al., 2017; Paduano et al., 2019; Staudacher et al., 2017)
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Table 4.1

Intervention Measures for Included Studies

First author (Year)

BSFS

IBS-SSS

Böhn et al. (2015)

✓

✓

Eswaran et al. (2016)

✓

Harvie et al. (2017)

Stool frequency and individual symptom scores for
abdominal pain, bloating, and urgency bloating (all assessed
by 11-point numerical rating
scale)
✓
✓

Hustoft et al. (2017)

✓

McIntosh et al. (2017)
Paduano et al. (2019)

✓

Patcharatrakul et al. (2019)

✓
Abdominal pain/discomfort, bloating, stool urgency, stool
frequency

Peters et al. (2016)

Staudacher et al. (2017)

✓

Zahedi et al. (2018)

✓

✓
GI VAS on IBS-SSS
Overall GI symptoms, abdominal pain, bloating, wind,
satisfaction with stool consistency,
and nausea
✓
GSRS
✓

BSFS, Bristol Stool Form Scale; IBS-SSS, IBS Severity Scoring System; GI VAS on IBS-SSS, Gastrointestinal Visual Analogue Scale on IBS
Severity Scoring System; GSRS, Gastrointestinal Symptom Rating Scale

Study summaries
Böhn et al. (2015)
Sixty-seven Rome III IBS participants of all four IBS subtypes 18-70 years of age, with a
mean age of 42.5±16.3 years and IBS-SSS score of ≥175 points in Sweden, were split into two
groups to follow the LFD or Traditional IBS dietary advice for 4 weeks. The Traditional IBS
dietary advice involved encouraging healthy eating and avoiding or reducing intake of large
meals, excessive fat, excessive fiber, caffeine, and gas producing foods like beans, cabbage, and
onions (see Table H.1). This was the first study to examine the effect of an LFD in an RCT with
an active comparator, that used a setup similar to that of a clinical setting. The investigators
knew the diets the patients were on, while the participants were blinded.
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For the LFD group, there were significant within group differences (see Table 4.3)
baseline to intervention in IBS-SSS scores in abdominal pain frequency (p=.008), abdominal
distension (p<.001), interference on life in general (p=.001), and stool frequency (p<.001).
The total LFD IBS-SSS score was significant within group difference from baseline (324±69) to
intervention (246±127) with p<.001 (see Table 4.3).
For the Traditional IBS diet group, there were significant within group differences from
baseline to intervention in IBS-SSS scores in abdominal pain frequency (p<.001), abdominal
distension (p=.003), dissatisfaction of bowel habit (p=.01), and interference on life in general
(p=.002). The Traditional IBS diet total IBS-SSS score was significant within group difference
from baseline (302±61) to intervention (236±78) with p<.001.
The main outcome of Böhn et al. (2015) was reduction in IBS-SSS scores (p<.001)
within both groups (see Table 4.3) and no significant difference between groups (see Table 4.4);
IBS-SSS VAS reduced to ≥50 points. Future studies should address the IBS subtypes and
difference in the effect of individual symptoms.
Eswaran et al. (2016)
Eighty-four Rome III IBS-D participants 19-75 years of age, with mean age 42.7±14.95
years with abdominal pain and BSFS of ≥5 points in the United States followed the LFD versus
dietary recommendations based upon modified guidance from the National Institute for Health
and Care Excellence (mNICE) for 4 weeks. The mNICE guidelines involved eating small
frequent meals, avoiding trigger foods, avoiding excess alcohol and caffeine; this diet included
FODMAP-containing foods (see Table H.1). This was the largest RCT as of 2016 and the only
study done in the United States that compared the LFD diet to the mNICE diet. The dietitians
knew the diet the patients were on, while the patients were blinded.
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The primary end point was to explore if the LFD provided adequate relief of overall IBS
symptoms during ≥50% of the last 2 weeks of the intervention. The secondary end point utilized
the Food and Drug Administration (FDA) composite outcome, which determines that a
"a ≥30% reduction in mean daily abdominal pain score and a decrease in mean daily BSFS value
of ≥1 compared with baseline for any 2 weeks of the 4-week study period), and the individual
components of the composite end point (≥30% reduction in mean daily abdominal pain score for
2/4 weeks or a decrease in mean daily BSFS value of ≥1 compared with baseline for 2/4 weeks)"
(Eswaran et al., 2016, p. 1826).
Fifty-two percent of the LFD experienced adequate relief of all IBS-D symptoms and
41% of the mNICE group (p=.31) during ≥50% of the last 2 weeks of the intervention. The
secondary outcome was a significantly greater proportion of participants in the LFD group
reported less abdominal pain compared to those in the modified NICE group (p=.008, 51%
improvement in abdominal scores with those in the LFD).
The LFD resulted in adequate relief of IBS-D symptoms of average daily scores of
abdominal pain, bloating, consistency, frequency, and urgency compared to the mNICE diet
group (see Table 4.3 and Table 4.4). The LFD showed better improvement with symptoms of
pain and bloating compared to the mNICE diet (see Table 4.3). Eswaran et al. (2016) emphasized
that LFD is not intended for long-term use. The main outcome was reduction in abdominal pain,
bloating, stool consistency, stool frequency, and urgency ≥50% weeks 3-4 of the study
(p<.0001).
Harvie et al. (2017)
Fifty Rome III IBS-C, IBS-D, and IBS-M participants with mean age of 41.95±13.55
years in New Zealand followed the LFD and Unrestricted diet. Group I followed the LFD, then
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introduced high FODMAPs after 3 months and Group II followed an Unrestricted diet, then
started an LFD after 3 months. The investigators and participants were not blinded.
Baseline to 3 months. Participants showed significant difference in total IBS-SSS scores
in group I (-144.5±89.0) compared to group II (-38.7 ± 74.8) (p<.01). Twenty out of 23
participants in Group I had IBS-SSS scores <175 (mild IBS) with 3 participants having IBS-SSS
score <50 points (similar to those without IBS), while Group II had 10 participants with mild
IBS, 17 with moderate IBS, and 3 with severe IBS.
At 3 months. Group I had a reduction in the maximum number of bowel motions
experienced per day (1.7±2.6) versus group II (0.1 ± 1.7) (p< .01) at 3 months; however, group II
at 6 months did not show this significance. At 3-6 months, the frequency of abdominal pain was
greatly reduced in group I (3.4 ± 2.9 d in 10) than group II (0.2 ± 1.9 d in 10) (p<.01). The effect
of the LFD for the severity of pain or abdominal distension was not significant in either group I
or II at 3 months.
During their intervention periods. The IBS-D participants had significant IBS-SSS
reduction in group I (114.5 ± 89) (p<.01) and group II (89 ± 81) (p<.01). Also, the IBS-M
participants showed a significant IBS-SSS reduction in group II (112±38) (p=.03). A subanalysis was not done for IBS-C since there was only a total of 5 participants. The Group II
intervention period showed a reduction in severity of pain (p=.02), frequency of pain (p=.03),
and abdominal distension (p =.01) (see Table 4.3).
At 6 months. Group I maintained clinical improvement overall even though highFODMAP foods were added back to the diet as tolerated; but some participants' IBS-SSS scores
classified them from mild to moderate and one from moderate to severe IBS. Group II showed
IBS-SSS scores typical of those with mild IBS or those without IBS.
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Main outcome. The IBS-SSS scores were lower in group I (275.6 ±63.6 to 128.8±82.5)
than group II (246.8±71.1 to 203.6±70.1) (p<.0002). At 3 months, the QoL increased in group I
(68.5±18.0 to 83±13.4) compared to group II (12.8 to 73.3 ±14.4) (p <.0001). At 6 months, the
reduction in IBS-SSS was maintained in group I (160±102) and repeated in group II (124±76)
(see Table 4.3 and Table 4.4).
Hustoft et al. (2017)
Twenty Rome III IBS-D and IBS-M participants with mean age of 34.6 years (18-52
years) with IBS-SSS score >175 in Norway followed the LFD for 9 weeks. The intervention was
LFD for 9 weeks; after 3 weeks of these 9 weeks, patients were randomized to receive a high
FOS supplement or maltodextrin (placebo) for 10 days. A limitation is that the researchers
excluded IBS-C patients. The researchers and participants were blinded.
After 3 weeks LFD and after 10-day FOS and placebo. Participants showed
improvement of all IBS-SSS symptoms with p<.001 for severity/frequency of abdominal pain,
severity of abdominal distension, and dissatisfaction with bowel habits, and interference on life
in general (see Table 4.3 and Table 4.4). Four out of five of the symptoms were worse in the
FOS than in the placebo (all except interference with life in general), so the LFD can show that
symptoms are likely to be reduced (see Table 4.4).
Main outcome. The total IBS-SSS showed a mean reduction of 163.8 and p<.001 of all
symptoms for the LFD group. There was a total IBS-SSS reduction ≥50 points (range 57-275
points) in all participants, describing sustainable symptom relief. No significant differences were
seen within the Unrestricted diet group.
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McIntosh et al. (2017)
Thirty-seven Rome III IBS participants of all four IBS subtypes, ≥18 years old with mean
age 50.88 years old in Canada followed the LFD versus Unrestricted diet for 3 weeks. The
patients were blinded, but the dietitian was not blinded to the intervention.
Baseline to intervention. Most IBS-SSS symptoms were significant for within group
LFD (see Table 4.3): abdominal pain intensity (p=.0019 or p<.01), dissatisfaction with bowel
habit (p=.0003), interference on life in general (p=.03), and total IBS-SSS (p=.0002 or p<.01).
There were no significant within group differences among the Unrestricted diet group. However,
there were two significant between LFD and Unrestricted diet differences (see Table 4.4):
abdominal pain intensity (p=.0065), abdominal pain frequency (p=.01) and total IBS-SSS score
(p=.01).
Main outcome. Patients that were defined as responders experienced an IBS symptom
reduction ≥50 points. Participants' total IBS-SSS for the LFD group was reduced to p<.001.
Paduano et al. (2019)
Thirty-four Rome IV IBS participants of all four IBS subtypes, 18-45 years old with
mean age 28.62±6.86 years in Italy followed the LFD versus the Balanced Mediterranean diet for
4 weeks. The Mediterranean diet involved maintaining intake of FODMAPs and glutencontaining food; increasing fiber intake; improving food habits in patients who are used to
skipping breakfast and snacks; and redistributing meals, calories and FODMAPs over a 24-hour
period (see Table H.1). The participants followed the diets in the same order. The health care
professionals and patients were not blinded.
Main outcome. Comparing LFD to the Balanced Mediterranean diet, participants had
within group differences of abdominal pain within 24 hours (p<.01), reduced VAS bloating
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(p<.01), reduced VAS pain (p<.01). There was reduced IBS-QoL (83±14, p<.01) for LFD (see
Table 4.3) and for Balanced Mediterranean diet (81±11, p<.01). The LFD group had within
group differences (see Table 4.3) with overall total IBS-SSS score (16 ±8, p<.01) and Balanced
Mediterranean (17±7, p< .01) over a period of 24 hours. The LFD, gluten-free, and Balanced
Mediterranean diets all improved overall IBS symptoms, bloating, abdominal pain, and quality
of life (Paduano et al., 2019). Greater reductions in quality of life and VAS pain were seen in the
Balanced Mediterranean diet; this diet was easier to follow than other two diets according to
Paduano et al. (2019) since it does not place an economic burden on participants within a fourweek period compared to the LFD and gluten-free diets.
Patcharatrakul et al. (2019)
Thirty-three Rome III IBS-C participants, 29 non-constipation IBS participants,
with a total of 62 participants completed the intervention, range from 18-70 years old with mean
age 51±14 years in Thailand with moderate to severe GI symptoms (defined as symptoms that
impaired their quality of life) followed the Structural Individual Low-FODMAP Dietary Advice
(SILFD) versus Brief Advice On A Commonly Recommended Diet (BRD) for 4 weeks. The
patients were blinded, but the investigators were not blinded to the intervention.
The SILFD involved a total of 3 thirty-minute sessions recognizing high-FODMAP foods
from an individual 7-day food diary, avoiding these foods, and taking a GI symptom
questionnaire (see Table H.1). The BRD involved a 5-minute session with the investigator in
which they did not use the word "FODMAP" and discussed avoiding large meals and reducing
trigger foods that cause gas, bloating, or abdominal pain: fruits, vegetables, nuts, beans, and
garlic (see Table H.1).
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The main study endpoint was to see if there was a difference in the number of subjects
who had "≥30% decrease in the average daily worst abdominal pain or abdominal discomfort
during the fourth week compared to the baseline" (Patcharatrakul et al., 2019, p. 3). The
secondary endpoint was to analyze GI symptom as well as stool frequency and stool consistency
(BSFS type 1–7).
Baseline to intervention. There were no significant between group differences in the
individual GI symptoms (abdominal pain/discomfort, bloating, stool urgency, and stool
frequency) (see Table 4.4) from baseline to intervention.
Baseline to post intervention. The SILFD group showed within group significance (see
Table 4.3) for abdominal pain (p=.001), abdominal discomfort (p<.001), bloating (p=.02), and
stool frequency times per week for IBS-C patients (p=.02). The BRD group showed within group
significance for stool frequency times per week for IBS-C patients (p=.001).
Main outcome. Patcharatrakul et al. (2019) concluded that 60% of moderate-to-severe
IBS patients experienced a reduction of maximum abdominal pain or discomfort by at least 30%
in the SILFD versus the BRD at 28% from baseline to the fourth week.
Peters et al. (2016)
Twenty-one Rome III IBS-C, IBS-D, and IBS-M participants aged ≥18 years old with
median age 34 (23-66 years) in Australia with celiac disease followed the LFD versus
Unrestricted diet for 6 weeks. The investigators and participants were not blinded.
Main outcome. From baseline to 6 weeks, the within group LFD (see Table 4.3) showed
highly significant difference in GI symptoms with IBS-SSS VAS score of p<.0001 for overall GI
symptoms (abdominal pain, bloating, intestinal gas (wind), stool consistency, and nausea). The
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within group LFD (see Table 4.3) also showed individual improved symptoms IBS-SSS VAS
score of p<.0001 for abdominal pain, bloating, intestinal gas (wind), and stool consistency.
Staudacher et al. (2017)
One hundred four Rome III IBS-D, IBS-M, and IBS-U participants, 18-65 years old with
mean age 33±12 years old in the United Kingdom followed the LFD versus Sham diet for 4
weeks. The Sham diet restricted a similar number of foods but maintained same FODMAP
intake; it included high and low FODMAP foods (see Table H.1). A limitation is that the
researchers excluded IBS-C patients. Investigators not involved in patient screening or
recruitment knew the diet patients were on, while the patients were blinded.
The LFD showed a lower total mean IBS-SSS score (173±95) than the Sham diet
(224±89) with between group difference of p=.001 (see Table 4.4). The LFD showed a lower
total mean for days of abdominal pain (30±27), distension severity (29±25), satisfaction with
bowels (42±23), change in IBS-SSS score (-117±86), compared with the Sham diet (44±29,
40±24, 53±17, -44±72, respectively) (see Table 4.4).
The GI Symptom Rating Scale (GSRS-IBS) questionnaire measures severity of
symptoms over the course of 7 days on a 3-point scale (0=absent, 1=mild, 2= moderate, and 3=
severe): abdominal pain, heartburn, acid reflux, nausea, borborygmi, bloating, belching,
flatulence, constipation, diarrhea, loose stool, hard stool, urgency, incomplete evacuation,
tiredness, and overall symptoms (Wiklund et al., 2003). In this study, the overall GSRS-IBS
severity score was slightly more significant in LFD (1.0±0.6) (see Table 4.3), compared to the
Sham diet (1.2±0.6) with between group difference of p=.020 (see Table 4.4). There were
significant GSRS-IBS scores between group differences of p=.001 for bloating, flatulence, and
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urgency; also significant between group difference for stool consistency with p=.008 (see Table
4.4).
There were no significant between groups differences in abdominal pain severity,
affecting life, constipation, diarrhea, loose stool, hard stool, incomplete evacuation, and stool
frequency (see Table 4.4). In terms of quality of life, LFD showed greater mean reductions of
role limitations due to physical health, energy/fatigue, body image, social reaction, and
relationships than the Sham diet.
Main outcome. The LFD group showed adequate relief of IBS symptoms in 61% of
patients compared with 39% of participants in the Sham dietary advice group for the per-protocol
analysis. The LFD group had overall significant difference with p<.001 and a 50-point reduction
in total IBS-SSS (see Table 4.3). However, there was no significant between group interactions
in adequate relief of symptoms with p=.52. Staudacher et al. (2017) conducted the largest
placebo controlled RCT with 104 IBS patients comparing the Sham diet versus LFD (with each
diet comparing to a probiotic). Fifty-one participants followed the Sham diet versus LFD.
Staudacher et al. (2017) resulted in 57% of the LFD patients experiencing adequate symptom
relief compared to 38% in the Sham diet group (shown in Table 4.2). Staudacher et al. (2017)
concluded that the LFD resulted in decreased levels of abdominal pain, bloating, flatulence,
urgency, and stool consistency.
Zahedi et al. (2018)
One hundred one Rome III IBS-D participants, 20-60 years old with mean age
37.52±12.18 years old in Iran with BSFS ≥5 points followed the LFD versus General Dietary
Advice (GDA) for 6 weeks. The participants were blinded, while the dietitians were not blinded
to the intervention.
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The GDA was derived from the British Dietetic Association and included the following
advice: limit caffeine, alcohol, spicy food, fatty food, and carbonated drinks; eat small frequent
meals; eat slowly and in peace; and avoid chewing gums and sweeteners containing polyols (see
Table H.1). The GI symptoms scores referred to the following: abdominal pain intensity,
abdominal pain frequency, abdominal distension, and bowel habit status.
Main outcome. The LFD resulted in reduced overall GI symptoms scores (p<.001), stool
frequency (p<.001), and consistency (p=.003) compared to the GDA group (see Table 4.4). The
LFD also resulted in greater reduction in overall scores of IBS-SSS, abdominal pain, distension,
consistency, and frequency from baseline to intervention than the GDA group (see Table 4.3).
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Figure 4.1

Flow Chart for Identification and Selection of Studies for the Systematic Review
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Table 4.2

Characteristics of Included Studies

First author
(Year)
Böhn et al.
(2015)

Country

Design/Methodology

Participants

Sample Size

Length of
Intervention
September
2013- March
2014
(4 weeks)

Predominant
Stool Type
IBS-C
IBS-D
IBS-M
IBS-U

Intervention

Main Outcomes

Sweden

RCT
Computer-generated
randomization, single
blinded

n= 56 females
n= 11 males
n= 84 recruited
n= 67
completed

Eswaran et al.
(2016)

United States

RCT
Computer-generated
randomization, single
blinded

Rome III IBS
18-70 years old,
mean age 42.5 ±
16.3 and IBSSSS score of
≥175
Rome III IBS-D
19-75 years old,
mean age 42.7 ±
14.95 with
abdominal pain
and BSFS ≥5

LFD vs.
Traditional
IBS diet

Reduction in IBS-SSS
(p<.001) within both
groups; no significant
difference between groups.
IBS-SSS reduced to ≥50

n= 65 females
n= 27 males
n= 171
recruited
n= 84
completed

October 2012November
2015
(4 weeks)

IBS-D

LFD vs.
mNICE diet

Rome III IBS,
mean age 41.95
± 13.55 years
old

n= 43 females
n= 7 males
n= 117
recruited
n= 50
completed

August 2011August 2012
(3 months)

IBS-C
IBS-D
IBS-M

Rome III IBS,
mean age 34.6
(18-52 years)
with IBS-SSS
score >175

n= 15 females
n= 5 males
n= 20 recruited
n= 20
completed

Fall 2015
(9 weeks)

IBS-D
IBS-M

Group I: LFD,
then
introduced
FODMAPs
after 3
months.
Group II:
Unrestricted
diet, then
started LFD
after 3
months.
LFD for 9
weeks; after 3
weeks of these
9 weeks,
randomized to
receive
supplement of
high
FODMAP or
maltodextrin
(placebo) for
10 days

Reduction in abdominal
pain, bloating, stool
consistency, stool
frequency, and urgency ≥
50% weeks 3-4 of the
study (p<.0001). FDA
composite endpoint with
>30% reduction in pain
and a reduction in BSFS of
>1.
The IBS-SSS scores were
lower in group I than
group II
(p<.0002), however the
QoL had increased
(p<.0001).

Harvie et al.
(2017)

New Zealand

RCT
Computer-generated
randomization, not blinded

Hustoft et al.
(2017)

Norway

RCT
Computer-generated
randomization, crossover
design, double blinded

Excluded IBS-C
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After 3 weeks on the LFD,
IBS-SSS showed mean
reduction total of 163.8
points and p<.001 of all
symptoms. IBS symptom
reduction ≥50. Sustainable
symptom relief.

Table 4.2 (continued)
First author
(Year)
McIntosh et al.
(2017)

Country

Design/Methodology

Participants

Sample Size

Length of
Intervention
June 2013November 2014
(3 weeks)

Predominant
Stool Type
IBS-C
IBS-D
IBS-M
IBS-U

Intervention

Main Outcomes

Canada

RCT
Computer-generated
randomization, parallel
design, single-blinded

Rome III IBS
≥18 years old,
mean age 50.88

Paduano et al.
(2019)

Italy

Non-RCT, consecutive
controlled study; not
blinded

Rome IV IBS
18-45 years old,
mean age 28.62
± 6.86 years

n= 32 females
n= 5 males
n= 40 recruited
n= 37
completed
n= 35 females
n= 7 males
n= 42 recruited
n= 34
completed

LFD vs.
Unrestricted
diet

Patients that were defined
as responders experienced
an IBS symptom reduction
≥50 points.

September
2018- October
2018
(4 weeks)

IBS-C
IBS-D
IBS-M
IBS-U

LFD vs.
Balanced
Mediterranean
diet

n= 32 females
n= 5 males
n= 40 recruited
n= 37
completed

June 2013November 2014
(3 weeks)

IBS-C
IBS-D
IBS-M
IBS-U

LFD vs.
Unrestricted
diet

Showed reduced abdominal
pain within 24 hours (p<
.01) and significant
difference in disease
severity through IBS-SSS
last 24 hours (p< .01).
Patients that were defined
as responders experienced
an IBS symptom reduction
≥50 points.

McIntosh et al.
(2017)

Canada

RCT
Computer-generated
randomization, parallel
design, single-blinded

Rome III IBS
≥18 years old,
mean age 50.88

Patcharatrakul
et al. (2019)

Thailand

RCT
Randomized by blocks of
four method, single
blinded

Rome III IBS
18-70 years old,
mean age 51 ±
14 years with
moderate-tosevere GI
symptoms
(defined as
symptoms that
impaired their
QoL)
Rome III IBS
≥18 years old,
median age 34
(23-66 years)
with celiac
disease

n= 47 females
n= 15 males
n= 70 recruited
n= 62
completed

Unknown date
range
(4 weeks)

33 IBS-C
29 nonconstipation

SILFD vs.
BRD

60% of moderate-to-severe
IBS patients experienced a
reduction of maximum
abdominal pain or
discomfort by at least 30%
in the SILFD versus the
BRD at 28% from baseline
to the fourth week.

Peters et al.
(2016)

Australia

RCT
Computer-generated
randomization, not
blinded

n= 19 females
n= 5 males
n= 146
recruited
n= 24
completed

Unknown date
range
(6 weeks)

IBS-C
IBS-D
IBS-M

LFD vs.
Unrestricted
diet

From baseline to 6 weeks,
highly significant
difference with GI
symptoms (p<.0001)

Staudacher et
al. (2017)

United Kingdom

RCT
Computerized random
allocation sequence,
single blinded

Rome III IBS
18-65 years old,
mean age 33 ±
12

n= 35 females
n= 16 males
n= 162
recruited
n= 51
completed

January 28,
2013November 21,
2014
(4 weeks)

IBS-D
IBS-M
IBS-U

LFD vs. Sham
diet

Adequate relief of IBS
symptoms and overall
significant difference with
p<.001 and a 50-point
reduction in IBS-SSS.

Excluded IBSC
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Table 4.2 (continued)
First author
(Year)
Zahedi et al.
(2018)

Country

Design/Methodology

Participants

Sample Size

Iran

RCT
Block randomization,
single blinded

Rome III IBS-D
20-60 years old,
mean age 37.52
± 12.18 with
BSFS ≥5

n= 51 females
n= 50 males
n=110 recruited
n= 101
completed

Length of
Intervention
February 2016August 2016
(6 weeks)

Predominant
Stool Type
IBS-D

Intervention

Main Outcomes

LFD vs. GDA
for IBS-D
patients

Improvement in GI
symptoms scores, stool
frequency, and consistency
(p< .001, p< .001 and
p=.003, respectively).
Significant reduction in
overall scores of IBS-SSS,
abdominal pain, distension,
consistency, and frequency.

RCT, Randomized Controlled Trial; LFD, Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD); IBS-SSS, IBS Severity
Scoring System; mNICE, modified National Institute for Health and Care Excellence; FDA, Food and Drug Administration; Bristol Stool Form Scale, BSFS; QoL, Quality of Life; SILFD, Structural
Individual Low-FODMAP Dietary Advice; BRD, Brief Advice on a Commonly Recommended Diet; GDA, General Dietary Advice
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Table 4.3

Included Study Results Compared to Systematic Review Objectives of LFD
Within Group Significance

First author (Year)

Abdominal
Pain
Severity/
Frequency

Abdominal
Distension/Bloating

Stool
Frequency

Stool
Consistency

Interference
on Life in
General
and/or
QoL

IBS-SSS Total Score

Böhn et al. (2015)

✓

✓

✓

NS

✓

✓

Eswaran et al.
(2016)

✓

✓

✓

✓

N/A

✓

Harvie et al. (2017)

✓

✓

✓

✓

✓

Hustoft et al. (2017)

✓

✓

✓ (max #
BM per
day)
N/A

N/A

✓

✓

McIntosh et al.
(2017)
Paduano et al.
(2019)
Patcharatrakul et al.
(2019)

Severity ✓

NS

N/A

N/A

✓

✓

VAS pain
✓
✓

VAS bloating ✓

N/A

✓

✓

✓

✓

✓

N/A

N/A

Abdominal
pain/discomfort,
bloating, stool
urgency, stool
frequency

Peters et al. (2016)

✓

✓

N/A

✓

✓

✓

Staudacher et al.
(2017)
Zahedi et al. (2018)

✓

✓

NS

✓

✓

GSRS and IBS-SSS ✓

✓

✓

✓

✓

✓

✓

*If significance within group, there is a check mark (✓).
NS, no significance; N/A, Not Applicable; QoL, Quality of life; IBS-SSS, IBS Severity Scoring System
LFD, LFD, Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD);
BM, bowel movement; VAS, Visual Analogue Scale; GSRS, Gastrointestinal Symptom Rating Scale

50

Table 4.4

Included Study Results Compared to Systematic Review Objectives of Between
Group Significance

First author
(Year)

Intervention

Abdominal
Pain
Severity/
Frequency

Abdominal
Distension/Bloating

Stool
Frequency

Stool
Consistency

Interference
on Life in
General
and/or
QoL

IBS-SSS Total
Score

Böhn et al.
(2015)

LFD vs.
Traditional
IBS diet

NS

NS

NS

NS

NS

NS

Eswaran et al.
(2016)

LFD vs.
mNICE diet

✓

✓

✓

✓

N/A

N/A

Harvie et al.
(2017)

LFD vs.
Unrestricted
diet

NS

NS

✓ (max #
BM per
day)

NS

✓

✓

Hustoft et al.
(2017)

LFD vs.
Unrestricted
diet

✓

✓

N/A

N/A

NS

✓

McIntosh et al.
(2017)

LFD vs.
Unrestricted
diet
LFD vs.
Balanced
Mediterranean
diet

✓

NS

N/A

N/A

NS

✓

VAS pain
NS

VAS bloating ✓

N/A

N/A

NS

NS

Paduano et al.
(2019)

Patcharatrakul
et al. (2019)

SILFD vs.
BRD

NS

NS

NS

N/A

N/A

Abdominal
pain/discomfort,
bloating, stool
urgency, stool
frequency

Peters et al.
(2016)

LFD vs.
Unrestricted
diet

NS

NS

N/A

NS

N/A

NS

Staudacher et
al. (2017)

LFD vs. Sham
diet

Frequency✓

✓

NS

✓

✓

GSRS-IBS and
IBS-SSS ✓

Zahedi et al.
(2018)

LFD vs. GDA
in IBS-D
patients

Severity ✓

✓

✓

✓

✓

✓

*If significance between group, there is a check mark (✓).
NS, no significance; N/A, Not Applicable; QoL, Quality of life; IBS-SSS, IBS Severity Scoring System
LFD, LFD, Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD);
mNICE, modified National Institute for Health and Care Excellence; BM, bowel movement; VAS, Visual Analogue Scale; SILFD, Structural
Individual Low-FODMAP Dietary Advice; BRD, Brief Advice on a Commonly Recommended Diet; GSRS, Gastrointestinal Symptom Rating
Scale; GDA, General Dietary Advice
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CHAPTER V
DISCUSSION
This systematic review compared 7 diets to the LFD to alleviate GI symptoms and quality
of life in IBS patients (Traditional IBS, mNICE, Unrestricted, Balanced Mediterranean, BRD,
Sham, and GDA). Traditional IBS and GDA diets alleviated abdominal
pain/frequency/severity/distension. The mNICE diet and Mediterranean diets helped with
abdominal pain and stool consistency, while significance in bloating was seen in the
Mediterranean diet. The LFD, Traditional IBS, GDA, and Mediterranean diets all showed
improvement in quality of life. Although LFD compared to the Unrestricted diet has been shown
to be effective for GI and quality of life symptoms in IBS patients, no significance difference
was seen when compared to Mediterranean diet, Traditional IBS diet, and GDA diets.
Abdominal pain/distension
All IBS subtypes
The LFD and the Traditional IBS diet were both effective for improving abdominal pain
frequency/distension with p<.05 for both groups for all IBS subtypes for within group
differences (Böhn et al., 2015). From baseline to 4-week intervention, the LFD showed
significance in IBS-SSS scores in abdominal pain frequency (p=.008) and abdominal distension
(p<.001) (see Table 4.3), while the Traditional IBS diet showed significance in IBS-SSS scores
in abdominal pain frequency (p<.001) and abdominal distension (p=.003) (Böhn et al., 2015).
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From baseline to 3-week LFD, IBS-SSS scores in abdominal pain intensity improved (p=.0019),
but no improvements in abdominal pain frequency (p=.07) (McIntosh et al., 2017).
Ironically, the Unrestricted diet only showed improvement in abdominal pain frequency
compared to the LFD (p=.03) (McIntosh et al., 2017). From baseline to 24-hours intervention,
both the LFD versus Mediterranean diets showed within group significances for reduced VAS
bloating 3±2 vs. 4±2 (p<.01) and reduced VAS pain 2±2 vs. 3±2, respectively (p<.01) (Paduano
et al., 2019).
IBS-C
From baseline to 4-week intervention, the SILFD had IBS-SSS significance for
abdominal pain (p=.001), abdominal discomfort (p<.001), and bloating (p=.02) (Patcharatrakul et
al., 2019).
IBS-D
After 4 weeks of LFD versus the mNICE diets, the LFD showed there to be 51%
improvement of abdominal pain (51% vs. 23%, p=.008) (Eswaran et al., 2016). Six weeks of
LFD and GDA diets resulted in improved IBS-SSS scores for abdominal pain
intensity/frequency and distension (p<.001 for within groups) and p=.035 for between groups
with GDA showing better improvement in abdominal distension (Zahedi et al., 2018).
IBS-C, IBS-D, IBS-M
Six weeks of LFD resulted in better IBS-SSS VAS score of p<.0001 for abdominal pain
and bloating compared to the Unrestricted diet (Peters et al., 2016). Similarly, 3 months on the
LFD resulted in reduced abdominal pain frequency (p<.01) compared to the Unrestricted diet
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(Harvie et al., 2017). Abdominal pain frequency showed continued reduction at 3-6 months
(p<.01) (Harvie et al., 2017).
IBS-D, IBS-M, and IBS-U
Four weeks of LFD versus the Sham diet resulted in the LFD having lower total mean for
days of abdominal pain (30±27, p=.001) and distension severity (29±25, p=.002) (Staudacher et
al., 2017).
IBS-D and IBS-M
Three weeks on the LFD and after the 10-day FOS supplement resulted in great reduction
in IBS-SSS in abdominal pain severity/frequency and distension (p<.001 for all) (Hustoft et al.,
2017).
Bowel habits
All IBS subtypes
Four weeks on the LFD caused there to be reduced IBS-SSS scores in stool frequency
(p<.001), while the Traditional IBS diet improved IBS-SSS scores in dissatisfaction of bowel
habit (p=.01) (Böhn et al., 2015). Three weeks on the LFD caused dissatisfaction of bowel habit
to improve (p=.0003) (McIntosh et al., 2017). Twenty-four hours on the LFD resulted in
improved BSFS compared to the Balanced Mediterranean diet (p=.03) (grade 3) (Paduano et al.,
2019).
IBS-C
The BRD showed better IBS-SSS scores than SILFD for stool frequency (p=.001 versus
p=.02, respectively) (Patcharatrakul et al., 2019).
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IBS-D
In a four-week intervention, IBS-D patients had within group LFD improvements for
stool frequency (p<.0001) and stool consistency (p<.0001) (Eswaran et al., 2016). Similarly,
when LFD was compared to the mNICE diet, IBS-SSS score for stool consistency was also
lowered (p<.0001 versus p=.0174, respectively) (Eswaran et al., 2016). Six weeks on the LFD
and GDA diets both resulted in improvement in IBS-SSS scores in stool frequency and
consistency, and dissatisfaction of intestinal transit (p<.001, p<.001, p<.001, respectively)
(Zahedi et al., 2018).
IBS-C, IBS-D, IBS-M
Baseline to 6-week LFD resulted in improved stool consistency (p<.0001) (Peters et al.,
2016). Likewise, baseline to 3 months LFD caused reduction in stool frequency (p<.01) (Harvie
et al., 2017).
IBS-D, IBS-M, and IBS-U
The 4-week LFD caused there to be lower total mean for satisfaction with bowels
(42±23) compared to the Sham diet (53±17) with p=.002 (Staudacher et al., 2017).
IBS-D and IBS-M
Three weeks on the LFD and after the 10-day FOS supplement resulted in IBS-SSS
reduction in dissatisfaction with bowel habits (p<.001) (Hustoft et al., 2017).
Quality of life
All IBS subtypes
Both the 4-week LFD and Traditional IBS diets resulted in improved IBS-SSS score for
interference with life in general (p=.001 versus p=.002, respectively) (Böhn et al., 2015);
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similarly, the 3-week LFD also had improved QoL (p=.03) (McIntosh et al., 2017). The 24-hour
LFD (83±14, p<.01) versus Balanced Mediterranean diet (81±11, p<.01) both resulted in
improved QoL (Paduano et al., 2019).
IBS-D
When followed for 6 weeks, the LFD and GDA diets resulted in improvements in
interference of daily life (p<.001, p<.001, respectively) (Zahedi et al., 2018).
IBS-C, IBS-D, IBS-M
From baseline to 6-week LFD, participants had improved QoL by 21 mean points
with mean of 57 (47–68) and p<.0001 (Peters et al., 2016). Comparably, 3 months on the LFD
resulted in improved IBS-SSS score in QoL (p<.05 for group I and p<.01 for group II) (Harvie et
al., 2017).
IBS-D, IBS-M, and IBS-U
The 4-week LFD (40±20) showed improved affecting life IBS-SSS score compared to the
Sham diet (47±21) with p=.022 (Staudacher et al., 2017).
IBS-D and IBS-M
The 3-week LFD and after 10-day FOS supplement resulted in IBS-SSS score reduction
in interference with life in general (p<.001) (Hustoft et al., 2017).
Other significant outcomes
Patients following the LFD consumed less fiber (33±17 grams/day to 21± 8 grams/day)
(p<.01) than those on the Unrestricted diet, however fiber intake increased once FODMAPs were
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reintroduced into the diet 27±9 grams/day (Harvie et al., 2017). The intestinal microbiome in
LFD and Unrestricted diets remained the same.
When followed for 3 weeks, the LFD lowered fecal bacteria (Actinobacteria,
Bifidobacterium, and Faecalibacterium prausnitzii), total short-chain fatty acids, n-butyric acid,
and serum levels of proinflammatory IL-6 and IL-8 (Hustoft et al., 2017). However, when the
patients took an FOS supplement, these bacteria levels decreased; but the cytokine and total
short-chain fatty acids levels stayed the same.
The LFD lactulose breath test showed less hydrogen production compared to the
Unrestricted diet, indicating no effect on the metabolome (McIntosh et al., 2017). The LFD
group resulted in significantly low levels of metabolite histamine (measure of immune
activation). Although the LFD did not show significant within group differences of phydroxybenzoic acid and azelaic acid, there were between group differences of histamine, phydroxybenzoic acid, and azelaic acid. The LFD caused lower amounts of Actinobacteria
richness and diversity, while the Unrestricted diet had lower abundance of bacteria involved in
gas consumption, hence causing GI symptoms. Histamine levels and the microbiota are believed
to cause GI symptoms in IBS patients.
Similar to McIntosh et al. (2017), the SILFD post-prandial hydrogen breath samples were
lower in the LFD; however, these levels were lower compared to the BRD group (Patcharatrakul
et al., 2019). An LFD caused a decrease in lowered intestinal hydrogen production.
Gut-directed hypnotherapy seemed to be just as effective as the LFD to improve GI
symptoms (Peters et al., 2016). Hypnotherapy helped with improving psychological indices from
baseline to 6 months.
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Similar to Hustoft et al. (2016), the LFD caused lower amounts of Bifidobacterium
species in fecal samples than those in the Sham diet (Staudacher et al., 2017). The
Bifidobacterium species were higher in the LFD group when they took a probiotic (9.1 rRNA
genes/gram) compared to those given the placebo (8.8 rRNA genes/gram) (P ¼ .019). Microbiota
diversity in fecal samples was the same in both diets, and this was also similar to Harvie et al.
(2017) Staudacher et al. (2017) recommends possibly taking a probiotic with Bifidobacterium
while following the LFD to prevent having lack of bacteria in the gut.
Agreements with prior systematic reviews
Dionne et al. (2018) concluded that there is not enough data to confirm the efficacy of
either an LFD or gluten-free diet alleviate symptoms in IBS-D patients or those experiencing
bloating. Also, the meta-analysis showed that there is unclear evidence to advise that patients
follow an LFD or gluten-free diet to effectively reduce global IBS symptoms. The evidence that
supports LFD reducing global IBS symptoms is poor; however, comparing LFD to other
available dietary interventions, LFD is the most effective for IBS.
Van Lanen et al. (2021) summarized that an LFD resulted in reduction of overall IBS
severity to moderate to a large extent and increased quality of life scores compared to a control
diet in a meta-analysis published in February 2021.
Hahn et al. (2021) found that an LFD alleviated symptoms and improved quality of life in
IBS patients when compared to controlled interventions in a meta-analysis published in July
2021. Patients who have IBS-D and followed LFD had improvement in stool frequency and
consistency. It is not established whether LFD is the best diet to alleviate symptoms, therefore, it
is important to undergo RCTs that account for efficacy predictors, discuss usages of LFD with
supplements or lifestyle changes, and long-term impacts.
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This systematic review is different from the previous three studies (Dionne et al., 2018;
Van Lanen et al., 2021; and Hahn et al., 2021) since it found the LFD to be effective for
abdominal pain frequency/distension/bloating, stool frequency/consistency/dissatisfaction of
bowel habit, and quality of life. The LFD could be recommended for alleviating abdominal pain
severity and quality of life in IBS patients.
Limitations
A big limitation of this systematic review was that only 10 articles were included in the
data analysis. There were several limitations of these 10 studies including small sample size,
inequal demographic representation, inequal representation of all IBS subtypes, not blinding
participants and investigators, lacking an RDN giving advice, and lacking diet randomization.
First, there was a small sample size with ranges from 20-101 participants, with an
average number of 53 participants. Also, this systematic review did not have a minimum time
frame requirement for LFD intervention, which was an issue with one study that was included
since it had only a 24-hour intervention (Paduano et al., 2019). The systematic review should
have required that studies have a limited time frame for LFD intervention for at least 2 weeks
since Monash University recommends following the diet for 2-6 weeks ("Treating IBS with a 3step FODMAP diet," 2019).
Secondly, the distribution of females to males in the studies was very disproportionate.
Irritable bowel syndrome is more commonly diagnosed in women (Oka et al., 2020, p. 6), and all
10 studies involved mostly women with a total of 398 females out of 530 participants who
completed the intervention, with an average number of 40 females per study, or 75.92% were
female. The average age of participants was 40.31±12.83 years, and this did not equally
represent younger IBS individuals. Also, the majority of the participants in three studies were of
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White ethnicity (Eswaran et al., 2016; Harvie et al., 2017; Staudacher et al., 2017), while the
other studies did not measure ethnicity at baseline (Böhn et al., 2015; Hustoft et al., 2017;
McIntosh et al., 2017; Paduano et al., 2019; Patcharatrakul et al., 2019; Peters et al., 2016;
Zahedi et al., 2018).
Thirdly, the studies did not equally represent all four IBS subtypes. Only three out of ten
studies included participants of all four IBS subtypes (Böhn et al., 2015; McIntosh et al., 2017;
Paduano et al., 2019). Four studies did not consist of participants with IBS-C (Eswaran et al.,
2016; Hustoft et al., 2017; Staudacher et al., 2017; Zahedi et al., 2018). Two studies did not
involve participants with IBS-M (Eswaran et al., 2016; Zahedi et al., 2018). Five studies did not
compare participants with IBS-U (Eswaran et al., 2016; Harvie et al., 2017; Hustoft et al., 2017;
Peters et al., 2016; Zahedi et al., 2018). Two studies only consisted of IBS-D patients (Eswaran
et al., 2016; Zahedi et al., 2018). Zahedi et al. (2018) only compared IBS-D patients due to the
researchers' biases that LFD could decrease bowel movements and make constipation worse,
while Eswaran et al. (2016) theorized since FODMAPs increase colonic fermentation and create
fermentation byproducts (like short-chain fatty acids) which due to their osmotic effects may
trigger diarrhea. Nevertheless, Eswaran et al. (2016) concluded that the LFD is most effective for
alleviating abdominal pain and bloating, but not bowel symptoms. Additionally, one study
included IBS-C patients and non-constipation patients, but the researchers failed to specify
subtypes (IBS-D, IBS-M, or IBS-U), so it is not possible to identify which subtypes, if any, were
excluded (Patcharatrakul et al., 2019). Also, advice given to IBS-C and IBS-non-constipation
patients could not be measured since the sample size was not big enough for a subgroup analysis
(Patcharatrakul et al., 2019).
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Fourthly, the participants were not equally blinded to the intervention. Three studies
involved participants that were not blinded (Harvie et al., 2017; Paduano et al., 2019; Peters et
al., 2016). Six studies were single-blinded, in which the participants did not know the diet they
were following whereas the investigator knew, which could have caused the RDN to give biased
observations and tell patients to avoid foods according to their diet (Böhn et al., 2015; Eswaran
et al., 2016; McIntosh et al., 2017; Patcharatrakul et al., 2019; Staudacher et al., 2017; Zahedi et
al., 2018). Therefore, patients could have guessed the type of diet they were following during the
intervention. For example, if following an LFD, patients would be told to include low-FODMAP
foods, while the Traditional IBS diet and GDA diets excluded gas-producing foods (Böhn et al.,
2015; Zahedi et al., 2018).
Fifthly, two studies had gastroenterologists or other unspecified professionals giving
dietary advice to participants (Hustoft et al., 2017; Patcharatrakul et al., 2019). These
investigators may not have the skills and training that a clinician such as an RDN has at
counseling patients on implementing dietary changes, which could lead to less dietary
compliance.
Finally, diet randomization was lacking in several studies:
•

One study had an imbalance of mNICE subjects compared to LFD group possibly due
to the computer-generated randomization strategy not including blocking (Eswaran et
al., 2016).

•

One study included participants that were aware of their group allocation, in which
group I followed LFD then introduced FODMAPs after 3 months and group II
followed restrictive diet and started LFD after 3 months (Harvie et al., 2017). Group
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II expected that their symptoms were to remain the same for the first 3 months
(Harvie et al., 2017).
•

One study only used FOS to represent a High-FODMAP diet or Unrestricted diet
(Hustoft et al., 2017). The researchers did not isolate the different FODMAPs to
analyze their effects on different patients (Hustoft et al., 2017).

•

The participants followed the diets in the same order (LFD, gluten-free, and Balanced
Mediterranean) without randomization (Paduano et al., 2019).

•

In one study, the patients were on an Unrestricted diet at baseline and followed the
LFD for 6 weeks (Peters et al., 2016). The patients knew that they were on the LFD
and were given detailed advice on the diet regarding high and low FODMAP foods,
instructions on reading food labels for FODMAPs, and recipe ideas (Peters et al.,
2016).

•

Staudacher et al. (2017) had challenges with blinding the participants to the diet
intervention, especially since the RDN had to teach about the Sham diet which
included similar exclusion foods as LFD and seemed as if it were LFD. Also, it was
not clear if patients had symptoms due to collective FODMAP restriction or removal
of one or several FODMAPs, and this could be due to including similar foods in both
the diet groups (Staudacher et al., 2017). Certain dietary components could not be
measured to compare differences in macronutrient intake; for example, patients could
have had changes in gluten or lactose intake depending on their diet (Staudacher et
al., 2017). Dietary intake change could have made an effect on other factors in the
study, such as stool frequency and this could alter the microbiota composition
(Staudacher et al., 2017).
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If all participants were double blinded to the intervention and provided meals with high and low
FODMAP foods, the researchers could better measure the efficacy of the diets due to diets being
randomized.
Overall improvement of symptoms
The LFD was most effective for abdominal pain frequency/distension, and bloating
compared to the Unrestricted diet (Böhn et al., 2015; Paduano et al., 2019; Harvie et al., 2017;
Staudacher et al., 2017). The LFD and GDA diets were equally effective for stool
frequency/consistency and dissatisfaction of bowel habits (Zahedi et al., 2018).
The LFD, GDA, and Traditional IBS diets were equally effective for abdominal pain
frequency/distension (Böhn et al., 2015; Zahedi et al., 2018; Hustoft et al., 2017). The Balanced
Mediterranean, LFD, mNICE, and GDA diets helped with stool consistency (Paduano et al.,
2019; Eswaran et al., 2016; Zahedi et al., 2018; Peters et al., 2016). The LFD, Traditional IBS
diet, GDA diets were all effective for improving dissatisfaction of bowel habits (McIntosh et al.,
2017; Böhn et al., 2015; Zahedi et al., 2018; Staudacher et al., 2017; Hustoft et al., 2017). The
majority of the diets resulted in increased QoL scores including LFD, Traditional IBS diet,
Balanced Mediterranean, and GDA (Böhn et al., 2015; McIntosh et al., 2017; Paduano et al.,
2019; Zahedi et al., 2018; Peters et al., 2016; Harvie et al., 2017 Staudacher et al., 2017; Hustoft
et al., 2017).
Effectiveness of other diets in the included studies
The LFD is superior to the Unrestricted diet in terms of abdominal pain
frequency/distension (Peters et al., 2016; Harvie et al., 2017; Hustoft et al., 2017; McIntosh et al.,
2017). The SILFD (a version of LFD) was superior to BRD in terms of abdominal
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pain/discomfort/bloating, and stool frequency (Patcharatrakul et al., 2019). IBS-C patients should
follow LFD or SILFD (Patcharatrakul et al., 2019), while IBS-D patients should follow the
mNICE diet for improving stool consistency (Eswaran et al., 2016). Patients with IBS-C, IBS-D,
IBS-M would benefit from following the LFD for pain/bloating, stool consistency/frequency,
and QoL. Patients with IBS-D, IBS-M, and IBS-U would benefit from LFD due to its
effectiveness over the Sham diet for pain/distension severity, satisfaction with bowels, and
affecting life IBS-SSS scores (Staudacher et al., 2017). The LFD should be followed for at least
4 weeks and up to 6 weeks to prevent having nutritional deficiencies; consumption of less
calories, less daily meals, less carbohydrates, and preventing altered microbiota (Staudacher et
al., 2020; Eswaran et al., 2020).
Findings of this systematic review
Even though other diets have been shown to alleviate GI symptoms and quality of life in
IBS patients, the LFD showed significance in improving abdominal pain
frequency/distension/bloating, stool frequency/consistency/dissatisfaction of bowel habit, and
quality of life. More notably, LFD can be recommended to patients to alleviate abdominal pain
severity and quality of life in IBS patients.
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CHAPTER VI
CONCLUSION
Clinical implications for dietetic practice
Irritable bowel syndrome is a functional GI disorder that has a 6.5% worldwide
prevalence (9.2% Rome III and 3.8% Rome IV criteria) that causes symptoms of gas production,
abdominal distension, and abdominal pain or discomfort. A common diet to manage these
symptoms is a diet low in FODMAPs, which helps to reduce colonic gas, mucosal inflammation,
and permeability, therefore preventing visceral hypersensitivity. The Academy of Nutrition and
Dietetics approves usage of the low-FODMAP diet to alleviate symptoms in patients who
manage functional GI symptoms due to 75% effectiveness of relief of symptoms and high
compliance rate ("MNT: Gastrointestinal Disorders," 2015; Gibson & Shepherd, 2010). The
findings of this systematic review are also in line with previous practice recommendations.
Future research
The LFD is effective for alleviating IBS symptoms for all IBS subtypes, however, there is
conflicting evidence on its efficacy for managing IBS-C symptoms. Future, double-blind
interventions with longer duration (6 months to one year), which provide pre-prepared meals
containing low and high FODMAP foods are needed, so that researchers are better able to
measure efficacy and compliance. Future research should also have more representative
demographic samples, including a balanced age, gender, and ethnic distribution.

65

While LFD is effective for alleviating abdominal pain severity and quality of life, it was less
effective for symptoms of abdominal pain frequency, distension, bloating, stool frequency, stool
consistency, and dissatisfaction of bowel habits. In conclusion, the LFD can be recommended to
patients for its use with alleviating abdominal pain severity and quality of life.
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Table A.1

List of Abbreviations

BRD

Brief Advice on a Commonly Recommended Diet

BSFS

Bristol Stool Form Scale

CENTRAL

Cochrane Central Register of Controlled Trials

CT Scan

Computed Tomography Scan

FDA

Food and Drug Administration

FODMAP

Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols

FOS

Fructo-oligosaccharides

GI

Gastrointestinal

GDA

General Dietary Advice

GSRS

Gastrointestinal Symptom Rating Scale

IBS

Irritable bowel syndrome

IBS-C

Irritable bowel syndrome with predominant constipation

IBS-D

Irritable bowel syndrome with predominant diarrhea

IBS-M

Irritable bowel syndrome with mixed bowel habits

IBS-SSS

Irritable bowel syndrome-severity scoring system

IBS-U

Irritable bowel syndrome, unclassified

LFD

Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides And
Polyols (FODMAP) diet (Low-FODMAP diet or LFD)

NICE

National Institute for Health and Care Excellence

MRI

Magnetic Resonance Imaging

PDF

Portable Document Format

PRISMA

Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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Table A.1 (continued)
RCT

Randomized controlled trial

RDN

Registered Dietitian Nutritionist

SILFD

Structural Individual Low-FODMAP Dietary Advice

SSRIs

Selective Serotonin Reuptake Inhibitors

VAS

Visual Analog Scale

vs.

Versus
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Table B.1

High and Low FODMAP Foods

FODMAP

High-FODMAP Foods

Low-FODMAP Foods

Oligosaccharides (fructans
and/or galactooligosaccharides)

Vegetables: artichokes,
asparagus, beetroot,
Brussels sprouts, broccoli,
cabbage, fennel, garlic,
leeks, shallots, okra, onions,
peas

Vegetables: carrot, cucumber,
potato, bell pepper, eggplant,
green beans, lettuce, spinach,
chives, parsnip, pumpkin, spring
onion (green only), tomato,
zucchini, bamboo shoots, Bok
Choy
Cereals: wheat-free grains or
wheat-free flours and products
made with these (e.g., bread,
pasta, crackers), spelt and spelt
products, oats, corn, rice,
quinoa
Legumes: canned chickpeas

Cereals: wheat & rye when
eaten in large amounts
(bread, pasta, crackers)

Disaccharides: Lactose

Monosaccharides:
Fructose

Legumes: chickpeas,
lentils, red kidney beans,
baked beans
Fruits: watermelon, white
peaches, rambutan
Milk (cow, goat, sheep),
yogurt, soft & fresh cheeses
(Ricotta, Cottage), ice
cream

Fruits: apples, pears,
clingstone peaches, mango,
sugar snap peas,
watermelon, canned fruit in
natural juice, dried fruits
Honey
Sweeteners: fructose, high
fructose corn syrup

Polyols

Fruits: apples, apricots,
cherries, nashi pears,
nectarines, pears, peaches,
plums, prunes, watermelon
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Lactose-free milk, rice milk,
almond milk, lactose-free
yogurt, hard cheeses (e.g.,
Cheddar, Parmesan, Swiss, Brie,
Camembert), butter, ice-cream
substitutes (e.g., dairy-free
gelato, sorbet)
Fruits: banana, blueberry,
grapefruit, grape, honeydew
melon, kiwifruit, lemon, lime,
mandarin, orange, tangelo,
raspberry, strawberry
Honey substitutes: maple
syrup
Sweeteners: sugar, glucose,
artificial sweeteners not ending
in “-ol”
Fruits: banana, blueberry,
grapefruit, grape, honeydew
melon, kiwifruit, lemon, lime,
mandarin, orange, raspberry

Table B.1 (continued)
FODMAP

High-FODMAP Foods
Vegetables: avocado,
cauliflower, mushrooms,
snow peas
Sweeteners: sorbitol,
mannitol, xylitol & others
ending in “-ol”, isomalt

Low-FODMAP Foods

Sweeteners: sugar, glucose,
artificial sweeteners not ending
in “-ol” (e.g., sucralose,
aspartame)

Source: Cozma-Petruţ, Loghin, Miere, and Dumitraşcu (2017, p. 3776)
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Table C.1

Diagnostic Criteria Used To Define Irritable Bowel Syndrome

Diagnostic Criteria

Signs and Symptoms Included in Criteria

Manning Criteriaa

Irritable bowel syndrome had 15 common symptoms associated with it. There were 31 out of
32 patients who experienced pain with IBS (no duration of symptoms). Three of the
following indicated a positive IBS diagnosis:
1. Looser stools at onset of pain
2. More frequent bowel movements at onset of pain
3. Pain eased after bowel movement (often)
4. Visible distension
5. Feeling of distension
6. Mucus per rectum
7. Feeling of incomplete emptying (often)
8. Bowel movement before breakfast
9. Nocturnal bowel movement
10. Urgency of defecation
11. Pain worse after bowel movement
12. Pain eased with flatus
13. >2 bowel movements between meals
14. Harder stools at onset of pain (least common)
15. Less frequent bowel movements at onset of pain (least common)

Kruis Criteriab

Irritable bowel syndrome was scored with a logistic regression analysis. Diagnosis was
based on probability rather than organic diseases.
Scoring System for a positive IBS Diagnosis
Irritable bowel syndrome scoring system for patients arriving at a clinic
Questions to be filled out by the patient:
1. Did you come because of abdominal pain? Do you suffer from flatulence? Do
you suffer from irregularities of bowel movement?
2. Have you suffered from your complaints for more than two years?
3. How can your abdominal pain be described: burning, cutting, very strong,
terrible, feeling of pressure, dull, boring, not so bad?
4. Have you noticed alternating constipation and diarrhea?
5. Have your stools any of the following properties: formed like a pencil, rabbit
pellets, formed and hard in the first portion and looser in the second one,
mucus?
Checklist to be filled out by the doctor:
1. Abnormal physical findings and/or history pathognomonic for any diagnosis
other than irritable bowel syndrome
2. Erythrocyte sedimentation rate > 20 mm/2 hr
3. Leukocytosis > 10.000/ccm
4. Anemia (Hemoglobin < 12% for women or < 14% for men)
5. History of blood in stool
6. Fever during the last week (>38.5°C)
7. Underweight (normal: kg = height – 100 cm)
8. Loss of weight exceeding 5 kg within the last 1/2 year
*Scored only if at least one statement in the first line or more than two statements in the total
were given
GI Symptoms Asked by Questionnaire in Patients with Organic Disease
•
A. Abdominal pain
•
B. Flatulence
•
C. Irregularities of bowel movement
•
Abdominal pain, flatulence, and irregularities of bowel movement in the same
patient
•
Above symptoms > 2 years
•
Characteristic of abdominal pain as described in above question- How can your
abdominal pain be described: burning, cutting, very strong, terrible, feeling of
pressure, dull, boring, not so bad?
•
Alternating bowel movements (constipation/diarrhea)
•
Pathologic stool properties
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Table C.1 (continued)
Rome Ⅰc

Continuous or recurrent symptoms for at least three months of:
1. Abdominal pain or discomfort, relieved with "defaecation", or associated
with a change in frequency or consistency of stool; and
2. An irregular (varying) pattern of defecation at least 25% of the time (three
or more of):
•
altered stool frequency;
•
altered stool form (hard or loose/watery stool);
•
altered stool passage (straining or urgency, feeling of incomplete
evacuation);
•
passage of mucus;
•
bloating or feeling of abdominal distension
Subtypes
C. Functional Bowel Disorders
C1. Irritable bowel syndrome
C2. Functional constipation
C3. Functional diarrhea
C4. Burbulence
C5. Unspecified functional bowel disorder

Rome Ⅱd

At least 12 weeks, which need not be consecutive, in the preceding 12 months of abdominal
discomfort or pain that has two of three features:
1. Relieved with defecation; and/or
2. Onset associated with a change in frequency of stool; and/or
3. Onset associated with a change in form (appearance) of stool
Supportive Symptoms of IBS
1. Fewer than three bowel movements a week
2. More than three bowel movements a day
3. Hard or lumpy stools
4. Loose (mushy) or watery stools
5. Straining during a bowel movement
6. Urgency (having to rush to have a bowel movement)
7. Feeling of incomplete bowel movement
8. Passing mucus (white material) during a bowel movement
9. Abdominal fullness, bloating or swelling
Diarrhea-predominant
1 or more of 2, 4, or 6 and none of 1, 3, or 5
Constipation-predominant
1 or more of 1, 3, or 5 and none of 2, 4, or 6

Subtypes
C. Bowel disorders
C1. Irritable bowel syndrome
C2. Functional abdominal bloating
C3. Functional constipation
C4. Functional diarrhea
C5. Unspecified functional bowel disorder
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Table C.1 (continued)
Rome Ⅲe

C1. Diagnostic Criteria* for Irritable Bowel Syndrome
Recurrent abdominal pain or discomfort** at least 3 days per month in the last 3
months associated with 2 or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
1. Onset associated with a change in form (appearance) of stool
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to
diagnosis.
**Discomfort means an uncomfortable sensation not described as pain. In
pathophysiology research and
clinical trials, a pain/discomfort frequency of at least 2 days a week during screening
evaluation for subject eligibility.

Supportive Symptoms
•
Abnormal stool frequency ([a] ≤ 3 bowel movements per week or [b] > 3
bowel movements per day)
•
Abnormal stool form ([c] lumpy/hard stool or [d] loose/watery stool)
•
[e] Defecation straining, [f] urgency, or also a feeling of incomplete bowel
movement, passing mucus, and bloating

Subtyping IBS by Predominant Stool Pattern
1. IBS with constipation (IBS-C)—hard or lumpy stoolsa
(mushy) or watery stoolsb <25% of bowel movements.c

≥ 25% and loose

2.

IBS with diarrhea (IBS-D)—loose (mushy) or watery stoolsb ≥ 25% and hard
or lumpy stoola <25% of bowel movements.c

3.

Mixed IBS (IBS-M)—hard or lumpy stoolsa ≥ 25% and loose (mushy) or
watery stoolsb ≥ 25% of bowel movements.c

4.

Unsubtyped IBS—insufficient abnormality of stool consistency to meet
criteria for IBS-C, D, or Mc

Note. To subtype patients according to bowel habit for research or clinical trials, the
following subclassification may be used.
The validity and stability of such subtypes over time is unknown and should be the
subject of future research.
a
Bristol Stool Form Scale 1–2 (separate hard lumps like nuts [difficult to pass] or
sausage shaped but lumpy).
b
Bristol Stool Form Scale 6–7 (fluffy pieces with ragged edges, a mushy stool or watery,
no solid pieces, entirely liquid).
c
In the absence of use of antidiarrheals or laxatives
Subtypes
C. Functional bowel disorders
C1. Irritable bowel syndrome
C2. Functional bloating
C3. Functional constipation
C4. Functional diarrhea
C5. Unspecified functional bowel disorder
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Table C.1 (continued)
Rome IVf

Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months,
associated with 2 or more of
the following criteria:
1. Related to defecation
2. Associated with a change in frequency of stool
3. Associated with a change in form (appearance) of stool
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months before
diagnosis.
Diagnostic Criteria for IBS Subtypes
Predominant bowel habits are based on stool form on days with at least one abnormal
bowel movement. a
•

•

•

•

IBS with predominant constipation: More than one fourth (25%) of bowel
movements with Bristol stool form types 1 or 2 and less than one-fourth
(25%) of bowel movements with Bristol stool form types 6 or 7. Alternative
for epidemiology or clinical practice: Patient reports that abnormal bowel
movements are usually constipation (like type 1 or 2 in the picture of Bristol
Stool Form Scale (BSFS) (see Figure 1.2)
IBS with predominant diarrhea (IBS-D): more than one fourth (25%) of
bowel movements with Bristol stool form types 6 or 7 and less than onefourth (25%) of bowel movements with Bristol stool form types 1 or 2.
Alternative for epidemiology or clinical practice: Patient reports that
abnormal bowel movements are usually diarrhea (like type 6 or 7 in the
picture of BSFS (see Figure 1.2)
IBS with mixed bowel habits (IBS-M): more than one fourth (25%) of bowel
movements with Bristol stool form types 1 or 2 and more than one-fourth
(25%) of bowel movements with Bristol stool form types 6 or 7. Alternative
for epidemiology or clinical practice: Patient reports that abnormal bowel
movements are usually both constipation and diarrhea (more than onefourth of all the abnormal bowel movements were constipation and more
than one-fourth were diarrhea, using picture of BSFS, (see Figure 1.2).
IBS unclassified (IBS-U): Patients who meet diagnostic criteria for IBS but
whose bowel habits cannot be accurately categorized into 1 of the 3 groups
above should be categorized as having IBS unclassified.

For clinical trials, subtyping based on at least 2 weeks of daily diary data is
recommended, using the “25% rule.”
a

IBS subtypes related to bowel habit abnormalities (IBSC, IBS-D, and IBS-M) can only
be confidently established when the patient is evaluated off medications used to treat
bowel habit abnormalities.
Subtypes
C. Functional bowel disorders
C1. Irritable bowel syndrome
C2. Functional constipation
C3. Functional diarrhea
C4. Functional abdominal bloating/distension
C5. Unspecified functional bowel disorders
C6. Opioid-induced constipation

Sources: a.Manning, Thompson, Heaton, and Morris (1978, p. 654). b.Kruis, Thieme, Weinzierl,
Schüssler, Holl, and Paulus (1984, pp. 2-3).c.Drossman, Thompson, Talley, Funch-Jensen,
Janssens, and Whitehead (1990, pp. 160, 165). d.Thompson, Longstreth, Drossman, Heaton,
Irvine, and Müller-Lissner (1999, pp. II43- II44). e.Longstreth, Thompson, Chey, Houghton,
Mearin, and Spiller (2006, pp. 1480- 1481). f.Lacy, Mearin, Chang, Chey, Lembo, Simren, and
Spiller (2016, pp. 1394- 1395)
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Figure D.1

Manning and Kruis Diagnostic Criteria Venn Diagrams

Sources: a. Manning, Thompson, Heaton, and Morris (1978, p. 654). b. Kruis, Thieme, Weinzierl,
Schüssler, Holl, and Paulus (1984, pp. 2-3).
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Figure D.2

Rome I and Rome II Diagnostic Criteria Venn Diagrams

Sources: c. Drossman, Thompson, Talley, Funch-Jensen, Janssens, and Whitehead (1990, pp.
160, 165). d. Thompson, Longstreth, Drossman, Heaton, Irvine, and Müller-Lissner (1999, pp.
II43- II44).
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Figure D.3

Rome III and Rome IV Diagnostic Criteria Venn Diagrams

Sources: e. Longstreth, Thompson, Chey, Houghton, Mearin, and Spiller (2006, pp. 1480- 1481).
f.
Lacy, Mearin, Chang, Chey, Lembo, Simren, and Spiller (2016, pp. 1394- 1395)
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Table E.1
Type 1
Type 2
Type 3
Type 4
Type 5
Type 6
Type 7

Bristol Stool Form Scale
Separate hard lumps, like nuts (difficult to pass)
Sausage-shaped, but lumpy
Like a sausage or snake, but with cracks on its surface
Like a sausage or snake, smooth and soft
Soft blobs with clear-cut edges (passed easily)
Fluffy pieces with ragged edges, a mushy stool
Watery, no solid pieces, entirely liquid

Source: Lewis & Heaton (1997, p. 921)

Table E.2

Rome III Subtyping IBS by Predominant Stool Pattern

IBS Subtype
IBS-C (IBS with constipation)

Bristol Stool Form Scale Bowel Habit
Hard or lumpy stools ≥25% (types 1-2)
Loose (mushy) or watery stools <25% (types 6-7)

IBS-D (IBS with diarrhea)

Loose (mushy) or watery stools ≥25% (types 6-7)
Hard or lumpy stool <25% (types 1-2)

IBS-M (Mixed IBS)

Hard or lumpy stools ≥25% (types 1-2)
Loose (mushy) or watery stools ≥25% (types 6-7)

IBS-U (Unsubtyped IBS)

Insufficient abnormality of stool consistency to meet
criteria for IBS-C, D, or M
Source: Longstreth, Thompson, Chey, Houghton, Mearin, & Spiller (2006, p. 1481)
* In the absence of use of antidiarrheals or laxatives
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Table F.1

Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS)

PATIENT SEVERITY SCORE QUESTIONNAIRE
IBS QUESTIONAIRE
Name:
G.P. Name:
Address:
Telephone
Date of birth:
Marital status: Single/ Married/ Divorced/Widowed/Co-Habit
Occupation:
Sex: Male/Female
Ethnic background: Caucasian (White)/Afro-Caribbean/Asian/Oriental
Father's Occupation (even if retired):
INSTRUCTIONS
This form is designed to enable us to record and monitor the severity of your IBS. It is to be
expected that your symptoms might vary over time, so please try and answer the questions based
on how you currently feel (i.e., over the last 10 days or so). All information will be kept in strict
confidence.
1. For questions where a number of different responses are a possibility, please circle the
response appropriate to you.
2. Some questions will require you to write in an appropriate response.
3. Some questions require you to put a cross on a line which enables us to judge the severity of
a particular problem.
For example:
How severe was your pain?
Please place your cross () anywhere on the line between 0-100% in order to
indicate as accurately as possible the severity of your symptom.
This example shows a severity of approximately 90%.
0% __________________________________________100%
no pain not very severe quite severe severe very severe

Source: Francis, Morris, & Whorwell, (1997, p. 401)
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Table F.1 (continued)

PART 1: SEVERITY SCORE
1.

a) Do you currently suffer from abdominal (tummy) pain? YES NO

For office use only
SCORE

b) If yes, how severe is your abdominal (tummy) pain?
0% ___________________________________________100%
no pain not very severe quite severe
severe very severe
c) Please enter the number of days that you get the pain in every 10 days.
For example, if you enter 4 it means that you get pain 4 out of 10 days. If you get
every day, enter 10.
Number of days with pain
2.

x10

a) Do you currently suffer from abdominal distension?* YES NO
(bloating, swollen, or tight tummy)
(women, please ignore distension related to your periods).
b) If yes, how severe is your abdominal distension/tightness?
0% _______________________________________________100%
no distension not very severe quite severe
severe very severe

3.

How satisfied are you with your bowel habit?
0% _______________________________________________100%
very happy
quite happy
unhappy
very unhappy

4.

Please indicate with a cross on the line below how much your irritable bowel
syndrome is affecting or interfering with your life in general.
0% _______________________________________________100%
not at all
not much
quite a lot
completely

IBS SEVERITY SCORE:

Source: Francis, Morris, & Whorwell, (1997, p. 401)
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Table F.1 (continued)
PART 2: OTHER IBS DATA

BOWEL HABIT
5. a) What is the most number of times you open your bowels per day/week/month?
Number of times

per day/week/month (Circle appropriate)

Note: For some people, the answer to part a and b could be the same.
b)What is the least number of times you open your bowels per day/week/month?
Number of times

per day/week/month (Circle appropriate)

6. In the following question, you may circle more than one answer:
Are your motions ever:
a) normal
often/occasionally/never (Circle appropriate)
b) hard

often/occasionally/never (Circle appropriate)

c) very thin (like string)

often/occasionally/never (Circle appropriate)

d) in small pieces (like rabbit pellets)

often/occasionally/never (Circle appropriate)

e) mushy (like porridge)

often/occasionally/never (Circle appropriate)

f) watery

often/occasionally/never (Circle appropriate)

7. In the following questions, you may circle more than one answer:
Do you ever:
a) pass mucus (or slime or jelly) with your motions?

YES

NO

b) pass blood with your motions?

YES

NO

c) have to hurry/rush to the toilet to open you bowels?

YES

NO

d) strain to open your bowels?

YES

NO

e) feel you haven't emptied your bowel completely
after you have passed a motion?

YES

NO

Source: Francis, Morris, & Whorwell, (1997, p. 402)
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Table F.1 (continued)
PART 2: Continued
SITE OF PAIN
Please mark with a cross () on the diagram below where you get your pain (use more than
one  if necessary)
*Original source shows a diagram of the torso.*

8. Do you ever:
a) notice your stools are more frequent or loose when you get pain?
b) notice whether the pain is frequently eased by opening your bowels?
9. In the last year on approximately how many weeks were you:
i) absent from work due to IBS
(enter 52 if you have given up completely work because of IBS)
ii) at work suffering from IBS

YES

NO

YES

NO

____ ____ ____
____ ____ ____

Source: Francis, Morris, & Whorwell, (1997, p. 402)
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Figure G.1

PRISMA Checklist

Source: Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidia, J. P.,
Clarke, M., Devereaux, P.J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement
for reporting systematic reviews and meta-analyses of studies that evaluate health care
interventions: Explanation and elaboration. Annals of Internal Medicine, 151(4), W-65W-94.
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Table H.1

Diets in the Included Studies

First author (Year)

Intervention

Description

What to Avoid/Reduce

Böhn et al. (2015)

LFD vs.
Traditional IBS diet

Traditional IBS diet: based on the
dietary recommendations from NICE
and the British Dietetic Association:
regular meal pattern (3 meals and 3
snacks/day); eat in peace and quiet,
chew thoroughly

Avoid large meals, avoid soft drinks and
carbonated beverages, chewing gums, and
sweeteners that ends with -ol

Same criteria as GDA

Reduce intake of fatty/spicy foods, caffeine,
alcohol; and gas-producing foods, such as beans,
cabbage, and onions, with greater emphasis on
how and when to eat
Distribute fiber intake throughout the day

Eswaran et al.
(2016)

LFD vs. modified
NICE guidelines diet

Modified NICE guidelines diet:
dietary recommendations for IBS
based on modified guidance from the
mNICE for patients with IBS-D; small
frequent meals, FODMAPs included

Avoid trigger foods, excess alcohol, and caffeine

Harvie et al. (2017)

LFD vs. Unrestricted
diet

Group I: LFD, then introduced
FODMAPS after 3 months.
Group II: Unrestricted diet, then
started LFD after 3 months.

Group I: LFD first 3 months
Group II: LFD after 3 months

Hustoft et al.
(2017)

LFD vs. Unrestricted
diet

LFD for 9 weeks; after 3 weeks of
these 9 weeks, randomized to receive
supplement of high FODMAP or
maltodextrin (placebo) for 10 days

McIntosh et al.
(2017)

LFD vs. Unrestricted
diet

Refer to Table C.1

Paduano et al.
(2019)

LFD vs. Balanced
Mediterranean Diet

Balanced Mediterranean diet:
maintained FODMAPs
and gluten-containing foods
Increase fiber intake, improve food
habits in patients who are used to
skipping breakfast and snacks, and
redistribute meals, calories and
FODMAPs over the 24-hour period
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Table H.1 (continued)
First author
(Year)

Intervention

Description

What to Avoid/Reduce

Patcharatrakul et
al. (2019)

SILFD vs. BRD

SILFD: Three 30-minute sessions;
individual 7-day food diary,
pamphlets given to patients

SILFD: Avoid high-FODMAP items and modify
recipe/menu with the commonly available lowFODMAP item

BRD: One 5-minute session dietary
advice from an investigator

BRD: Reduce certain foods recognized as triggers
for gas, bloating, or abdominal pain: fruits,
vegetables, nuts, beans, and garlic. Avoid large
meals.
The word "FODMAP" was not used in the session.

Peters et al.
(2016)

LFD vs. Unrestricted
diet

Refer to Table C.1

Staudacher et al.
(2017)

LFD vs. Sham diet

Sham diet: restricted a similar
number of staple and non-staple foods
and requires similar difficulty of
dietary change to the LFD; similar
intensity and duration of dietary
counselling as the LFD; and not to
impact on intakes of nutrients, fiber,
and FODMAPs. Allowed apples,
bananas, pears, and wheat

Sham diet: excluded oranges, raspberries, and
strawberries; excluded rice

High-FODMAP foods allowed:
apples, pears, wheat
Includes high and low FODMAP
foods; control diet

Zahedi et al.
(2018)

LFD vs. GDA
in IBS-D patients

GDA: dietary recommendations from
British Dietetic Association; eat small
frequent meals; to eat slowly and in
peace

GDA: Limit intake of caffeine, spicy/fatty foods,
carbonated drinks; avoid chewing gums and
sweeteners containing polyols

Same criteria as Traditional IBS diet

LFD, LFD, Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAP) diet (Low-FODMAP diet or LFD);
NICE, National Institute for Health and Care Excellence; GDA, General Dietary Advice; mNICE, modified National Institute for Health and Care
Excellence; SILFD, Structural Individual Low-FODMAP Dietary Advice; BRD, Brief Advice on a Commonly Recommended Diet
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